US20090263417A1 - Multi-subtype FIV vaccines - Google Patents
Multi-subtype FIV vaccines Download PDFInfo
- Publication number
- US20090263417A1 US20090263417A1 US11/803,033 US80303307A US2009263417A1 US 20090263417 A1 US20090263417 A1 US 20090263417A1 US 80303307 A US80303307 A US 80303307A US 2009263417 A1 US2009263417 A1 US 2009263417A1
- Authority
- US
- United States
- Prior art keywords
- fiv
- fet
- shi
- virus
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 208000015181 infectious disease Diseases 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000001681 protective effect Effects 0.000 claims abstract description 10
- 230000002163 immunogen Effects 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- 229920002866 paraformaldehyde Polymers 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims 7
- 241000282326 Felis catus Species 0.000 abstract description 76
- 241000700605 Viruses Species 0.000 abstract description 33
- 241000282324 Felis Species 0.000 abstract description 16
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 4
- 230000028996 humoral immune response Effects 0.000 abstract description 4
- 241000713800 Feline immunodeficiency virus Species 0.000 description 187
- 210000004027 cell Anatomy 0.000 description 184
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 31
- 230000003053 immunization Effects 0.000 description 29
- 238000002649 immunization Methods 0.000 description 29
- 238000003752 polymerase chain reaction Methods 0.000 description 27
- 108010002350 Interleukin-2 Proteins 0.000 description 26
- 102000000588 Interleukin-2 Human genes 0.000 description 26
- 238000003556 assay Methods 0.000 description 25
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 230000003612 virological effect Effects 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 102100034349 Integrase Human genes 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 238000002255 vaccination Methods 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000003119 immunoblot Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 230000005101 cell tropism Effects 0.000 description 5
- 239000012531 culture fluid Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000001566 pro-viral effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000714165 Feline leukemia virus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010015780 Viral Core Proteins Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- -1 threonyl muramyl dipeptide Chemical compound 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 241000714174 Feline sarcoma virus Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002976 reverse transcriptase assay Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- DPXDVGDLWJYZBH-GUBZILKMSA-N Arg-Asn-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O DPXDVGDLWJYZBH-GUBZILKMSA-N 0.000 description 1
- OVQJAKFLFTZDNC-GUBZILKMSA-N Arg-Pro-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O OVQJAKFLFTZDNC-GUBZILKMSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- TWHDOEYLXXQYOZ-FXQIFTODSA-N Gln-Asn-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N TWHDOEYLXXQYOZ-FXQIFTODSA-N 0.000 description 1
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 1
- YDWZGVCXMVLDQH-WHFBIAKZSA-N Gly-Cys-Asn Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(N)=O YDWZGVCXMVLDQH-WHFBIAKZSA-N 0.000 description 1
- IMRNSEPSPFQNHF-STQMWFEESA-N Gly-Ser-Trp Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)O IMRNSEPSPFQNHF-STQMWFEESA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- DPUOLKQSMYLRDR-UBHSHLNASA-N Phe-Arg-Ala Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 DPUOLKQSMYLRDR-UBHSHLNASA-N 0.000 description 1
- PBWNICYZGJQKJV-BZSNNMDCSA-N Phe-Phe-Cys Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CS)C(O)=O PBWNICYZGJQKJV-BZSNNMDCSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- DPMVSFFKGNKJLQ-VJBMBRPKSA-N Trp-Glu-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N DPMVSFFKGNKJLQ-VJBMBRPKSA-N 0.000 description 1
- UPNRACRNHISCAF-SZMVWBNQSA-N Trp-Lys-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 UPNRACRNHISCAF-SZMVWBNQSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
Definitions
- the subject invention was made with government support under a research project supported by National Institutes of Health Grant No. NIH AI30904. The government has certain rights in this invention.
- FeLV feline leukemia virus
- FeSV feline sarcoma virus
- RD-114 endogenous type C oncoronavirus
- FeSFV feline syncytia-forming virus
- FeLV is the most significant pathogen, causing diverse symptoms including lymphoreticular and myeloid neoplasms, anemias, immune-mediated disorders, and an immunodeficiency syndrome that is similar to human acquired immune deficiency syndrome (AIDS).
- AIDS human acquired immune deficiency syndrome
- FeLV-AIDS a particular replication-defective FeLV mutant, designated FeLV-AIDS, has been more particularly associated with immunosuppressive properties.
- feline T-lymphotropic lentivirus now designated as feline immunodeficiency virus, FIV
- FIV feline immunodeficiency virus
- FIV infection of cats is now considered to be a better feline AIDS model than FeLV-FAIDS.
- FIV virus subtypes can be classified according to immunotype based on the level of cross-neutralizing antibodies elicited by each strain (Murphy and Kingsbury, 1990). Recently, viruses have been classified into subtypes according to genotype based on nucleotide sequence homology.
- FIV viral isolates are currently classified into four FIV subtypes: A, B, C and D. (Kakinuma et al., 1995). Infectious isolates and infectious molecular clones have been described for all FIV subtypes except for subtype C (Sodora et al., 1994). Subtype C FIV has only been identified from cellular DNA of cats from Canada (Sodora et al., 1994; Rigby et al., 1993; Kakinuma et al., 1995).
- the subject invention concerns a vaccine that elicits a broad range of protective immunity against FIV infections in a host animal.
- the subject invention concerns a multi-subtype FIV vaccine that is prepared using cell-free viral isolates from different FIV subtypes, or a combination of cell lines each infected with a different prototype FIV virus from a different subtype.
- Cats vaccinated with the FIV vaccines of the subject invention develop humoral and cellular immune responses to homologous and heterologous FIV strains.
- the subject invention also concerns novel feline cell lines that are susceptible to infection by multiple FIV subtypes.
- the cell lines of the subject invention are useful for propagating and producing multiple FIV subtypes, as well as for use in FIV vaccines according to the methods of the subject invention.
- the cell lines can also be used in place of feline peripheral blood mononuclear cells (PBMC) in FIV viral neutralization assays of feline antisera.
- PBMC peripheral blood mononuclear cells
- FIG. 1 shows the reverse transcriptase (RT) levels of FIV Bang and FIV Shi produced after infecting FeT-1C and FeT-J cell lines with these FIV strains.
- FIG. 2 shows the immunoreaction of anti-FIV antibodies from dual-subtype vaccinated cats with FIV proteins as detected by immunoblot. The number over each blot represent the number of vaccinations received by the animal when the sera was tested.
- FIG. 3 shows the immunoreaction of anti-FIV antibodies from triple-subtype vaccinated cats with FIV proteins as detected by immunoblot. The number over each blot represent the number of vaccinations received by the animal when the sera was tested.
- FIG. 4 shows the immunoreactivity of anti-FIV antibodies from triple-subtype vaccinated cats with FIV SU-V3-2 peptide as detected by ELISA.
- FIG. 5 shows the immunoreactivity of anti-FIV antibodies from triple-subtype vaccinated cats with FIV TM-C1 peptide as detected by ELISA.
- FIG. 6 shows cross-neutralizing antibody titers of sera from cats infected with either FIV Pet (A P ), FIV Dix (A D ), FIV UK8 (A U ), FIV Bang (B B ), FIV Aom1 (B A ), and FIV Shi (D S ).
- Sera at pre-infection (column 1), 6 months post-infection (column 2), and 12 months post-infection (column 3) were tested against subtype A FIV Pet , subtype B FIV Bang , and subtype D FIV Shi in the FeT-1C-cell line.
- At least three cats per each strain were tested and results show VN titer from a representative cat from each strain. Similar results were obtained using primary PBMC for VN assay.
- SEQ ID NO: 1 is an amino acid sequence of an FIV surface envelope peptide designated as SV-V3-2.
- SEQ ID NO: 2 is an amino acid sequence of an FIV transmembrane peptide designated as TM-C1.
- SEQ ID NO: 3 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 4 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 5 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 6 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 7 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 8 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 9 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 10 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 11 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 12 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 13 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 14 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 15 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 16 is a nucleotide sequence of an FIV PCR primer.
- the subject invention concerns novel methods and vaccine compositions useful for inducing protective immunity to FIV infection in a susceptible host animal.
- the vaccine compositions described herein when administered to a host animal, induce protective humoral and cellular immune responses against infection by homologous and heterologous strains of FIV.
- the vaccine compositions may comprise either cell-free FIV viral isolates or FIV-infected cell lines.
- the vaccine composition of the subject invention comprises FIV strains from two different FIV subtypes.
- the vaccine composition comprises three FIV strains, each strain from a different FIV subtype. More preferably, at least one FIV strain from each of FIV subtype A, subtype B and subtype D is included in the vaccine composition.
- the vaccine composition comprises FIV Pet - and FIV Shi -infected cell lines.
- the vaccine composition comprises FIV Pet -, FIV Bang -, and FIV Shi -infected cell lines.
- FIV strains representative of all or a portion of FIV subtypes is specifically contemplated by the subject invention.
- FIV Dix or FIV UK8 could be included in the vaccine compositions in addition to or in place of FIV Pet for purposes of providing an FIV subtype A prototype virus. Similar additions or substitutions with other FIV strains could be made for FIV subtype B and D prototype viruses.
- the vaccine compositions of the subject invention may comprise cell-free whole FIV virus, or portions of the virus, FIV proteins and polypeptides, as well as FIV-infected cell lines, or a combination of cell-free virus and infected cell lines.
- Vaccine compositions comprising FIV-infected cell lines may comprise multiple cell lines, each infected with a different FIV subtype.
- the vaccine compositions of the subject invention also encompass recombinant viral vector-based FIV constructs that may comprise, for example, FIV env, gag/pro, or env-gag/pro. Any suitable viral vector that can be used to prepare recombinant vector/FIV constructs is contemplated for use with the subject invention.
- viral vectors derived from adenovirus, avipox, feline herpesvirus, vaccinia, canarypox, entomopox, swinepox and others known in the art can be used with the compositions and methods of the present invention.
- Recombinant polynucleotide vectors that encode and express FIV components can be constructed using standard genetic engineering techniques known in the art.
- the various vaccine compositions described herein can be used separately and in combination with each other.
- primary immunizations of an animal may use recombinant vector-based FIV constructs, having single or multiple subtype components, followed by secondary boosts with vaccine compositions comprising inactivated FIV-infected cell lines.
- Other immunization protocols with the vaccine compositions of the invention are apparent to persons skilled in the art and are contemplated within the scope of the present invention.
- the multi-subtype FIV vaccines specifically described herein were tested for immunogenicity and efficacy in cats.
- Specific pathogen free (SPF) cats vaccinated with the subject vaccine compositions were monitored for humoral and cellular immune responses before and after challenge with homologous and heterologous FIV strains.
- Humoral responses were monitored by measuring viral neutralizing (VN) antibody activity and cellular responses were monitored by measuring cytotoxic T lymphocyte (CTL) activity.
- VN viral neutralizing
- CTL cytotoxic T lymphocyte
- Sera and immunocytes from vaccinated cats were tested in vitro for VN and CTL activities, respectively, against homologous and heterologous FIV strains, and demonstrated that the vaccines can elicit broad-range protection from FIV infection.
- an effective multi-subtype FIV vaccine can be produced.
- FIV strains in addition to those specifically exemplified herein, are contemplated for use with the subject invention.
- a number of FIV isolates have been described in the literature and are known to those skilled in the art.
- FIV Pet has been described in U.S. Pat. No. 5,037,753.
- Other FIV isolates which have been described can be readily isolated from infected cats by persons of ordinary skill in the art using standard techniques. Methods for isolating and culturing FIV are described in U.S. Pat. Nos. 5,037,753 and 5,118,602, which are herein incorporated by reference.
- novel cell lines exemplified herein can be used in the vaccine methods and compositions of the present invention.
- Other cells or cell lines that are susceptible to infection by FIV strains, including peripheral blood mononuclear cells, are also contemplated for use with the present invention.
- FIV polypeptides derived from multiple FIV subtypes are combined in a vaccine composition and are used to vaccinate a host animal.
- polypeptides based on the FIV envelope glycoprotein from at least two prototype FIV strains from different subtypes can be combined in the vaccine.
- the polypeptides may be homologous to one strain or may comprise “hybrid” or “chimeric” polypeptides whose amino acid sequence is derived from joining or linking polypeptides from at least two distinct FIV subtypes.
- FIV polypeptides can be synthesized using solid-phase synthesis methods (Merrifield, 1963). FIV polypeptides can also be produced using recombinant DNA techniques wherein a polynucleotide molecule encoding an FIV protein or peptide is expressed in a host cell, such as bacteria, yeast, or mammalian cell lines, and the expressed protein purified using standard techniques of the art.
- the present invention also concerns novel feline T-cell lines that are susceptible to infection by FIV.
- Both interleukin-2 (IL-2) dependent and independent cells are specifically exemplified.
- the cell lines designated as FeT-1C and FeT-J are described herein.
- the FeT-1C cell line is IL-2 dependent, whereas the FeT-J cell line is IL-2 independent.
- the cell lines of the subject invention are useful for providing a vehicle for FIV immunization of cats, as well as for propagating and producing FIV viral strains in vitro.
- Both the IL-2-dependent FeT-1C and IL-2-independent FeT-J uninfected cell lines were tested over 20 times for reverse transcriptase (RT) activity in culture fluids and for FIV proviral sequence by PCR and were confirmed negative for FIV.
- FeT-J cell line was highly infectable with all of the FIV strains tested, including FIV Shi , FIV Dix , FIV UK8 , FIV Pet and FIV Bang but was more difficult to directly infect with FIV Shi .
- the subject invention further concerns cellular products produced by the cell lines of the present invention.
- the cellular products can be isolated and detected using procedures known to the skilled artisan.
- Antibodies to the cell lines can also be produced using known methods and are contemplated by the subject invention.
- FIV uninfected cell lines designated as FeT-1C (ATCC Accession No. CRL 11968) and as FeT-J (ATCC Accession No. CRL 11967) were both deposited with the American Type Culture Collection, Rockville, Md. on Aug. 24, 1995.
- FIV Bang -(ATCC Accession No. 11975) and FIV Shi -(ATCC Accession No. 11976) infected cell lines were deposited with the American Type Culture Collection on Aug. 25, 1995.
- the subject culture deposit will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of Microorganisms, i.e., it will be stored with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposit, and in any case, for a period of at least thirty (30) years after the date of deposit or for the enforceable life of any patent which may issue disclosing the culture.
- the depositor acknowledges the duty to replace the deposit should the depository be unable to furnish a sample when requested, due to the condition of the deposit. All restrictions on the availability to the public of the subject culture deposit will be irrevocably removed upon the granting of a patent disclosing it.
- the FIV vaccine compositions described herein are administered to susceptible hosts, typically domestic cats, in an effective amount and manner to induce protective immunity against subsequent challenge or infection of the host by FIV.
- the vaccines are typically administered parenterally, by injection, for example, either subcutaneously, intraperitoneally, or intramuscularly. Other suitable modes of administration include oral or nasal administration.
- the vaccines are administered to a host at least two times, with an interval of one or more weeks between each administration.
- other regimens for the initial and booster administrations of the vaccine are contemplated, and may depend on the judgment of the practitioner and the particular host animal being treated.
- the vaccine compositions of the subject invention can be prepared by procedures well known in the art.
- the vaccines are typically prepared as injectables, e.g., liquid solutions or suspensions.
- the vaccines are administered in a manner that is compatible with dosage formulation, and in such amount as will be therapeutically effective and immunogenic in the recipient.
- the optimal dosages and administration patterns for a particular vaccine formulation can be readily determined by a person skilled in the art.
- Virus and cells in a vaccine formulation may be inactivated or attenuated using methods known in the art. For example, whole virus and infected cells can be inactivated or attenuated. by exposure to paraformaldehyde, formalin, phenol, UV light, elevated temperature and the like.
- the amount of cell-free whole FIV virus in a vaccine dose will usually be in the range from about 0.1 mg to about 5 mg, and more usually being from about 0.2 mg to about 2 mg.
- the dosage for vaccine formulations comprising FIV-infected cell lines will usually contain from about 10 6 to about 10 8 cells per dose, and more usually from about 5 ⁇ 10 6 to about 7.5 ⁇ 10 7 cells per dose.
- Virus or cells were typically combined with an adjuvant just prior to administration.
- adjuvants used in the vaccine formulations typically were either threonyl muramyl dipeptide (MDP) (Byars et al., 1987) or a combination of Freud's complete and incomplete adjuvants.
- MDP threonyl muramyl dipeptide
- Freud's complete and incomplete adjuvants a variety of other adjuvants suitable for use with the methods and vaccines of the subject invention, such as alum, are well known in the art and are contemplated for use with the subject invention.
- the subject invention further concerns a novel method for assaying for virus neutralizing (VN) antibodies in a sample using the uninfected cell lines of the present invention.
- VN virus neutralizing
- the FeT-1C and FeT-J cells are an established cell line and can be readily cryopreserved for future use. Results obtained from VN assays using FeT-1C cells are more highly reproducible than VN assays using PBMC because PBMC from different SPF cats have individual variability in cell growth rate and FIV infectability.
- PBMC for VN assays have to be obtained from SPF cats which require germ-free housing and maintenance in order to eliminate possible in vivo infection which may affect an in vitro VN assay using PBMC.
- a feline cell line such as FeT-1C which can be readily infected with FIV of different subtypes can be advantageously substituted for PBMC in VN assays.
- TCF tissue culture fluids
- Tissue culture fluids from FIV-infected cell lines were individually centrifuged at 2000 to 3000 rpm for 1 hr to remove cells.
- Virus in the TCF was pelleted by ultracentrifugation at 16,000 rpm for 2 hours, and purified by ultracentrifugation first on a 10/50% (w/v) discontinuous sucrose gradient and then on a 10/50% continuous sucrose gradient (Pederson et al., 1987; Yamamoto et al., 1988).
- Each of the viral isolates was inactivated with 1.25% sterile paraformaldehyde (0.22 ⁇ m sterile filtered) for 18 hr and subsequently extensively dialyzed against sterile PBS.
- the inactivated viruses were diluted to a concentration of 500 ⁇ g/ml with sterile PBS and 250 ⁇ g/0.5 ml of each strain was placed in sterile microfuge tube and stored at ⁇ 70° C.
- the inactivated FIV strains were thawed at room temperature and 250 ⁇ g of inactivated virus in 0.5 ml sterile PBS was combined with 0.5 ml of adjuvant just prior to immunization.
- FIV-infected cell lines were separately inactivated with 1.25% sterile paraformaldehyde for 18 hr, washed 3 times with sterile PBS, resuspended in fresh sterile PBS at concentration of about 5.0 ⁇ 10 7 cells/ml in sterile tubes and stored at 4° C.
- sterile PBS Typically, about 2.5 ⁇ 10 7 inactivated infected cells in 0.5 ml sterile PBS were combined with 0.5 ml of adjuvant just prior to immunization. 250 ⁇ g/0.5 ml of threonyl muramyl dipeptide (MDP MF75.2 adjuvant; Chiron Corporation, Emeryville, Calif.) was used as an adjuvant.
- PBMC Peripheral blood mononuclear cells
- Concanavalin A Con A
- FIV FIV for 10 days
- CTL activity was generated by co-culturing Con A-stimulated PBMC with autologous UV- and radiation inactivated FIV-infected PBMC for 5 days. These cells served as the stimulated effector cells.
- target cells were labeled with 50 ⁇ Ci of Na 51 CrO 4 for 1 to 3 hours, washed 3 times, and then a fixed number of labeled target cells (5 ⁇ 10 4 cells/well) were added to microtiter plates.
- Effector cells were added in triplicate at various effector/target cell ratios (i.e., 100:1, 50:1, and 10:1). Plates were centrifuged for 1 minute at 400 rpm and incubated at 37° C. for 4 hours. Control 51 Cr-labeled target cells were lysed with detergent to obtain maximal release values. Supernatants from the test sample wells were collected and radiation was quantified using a gamma counter. Spontaneous release was determined by incubating 51 Cr-labeled target cells in the absence of effector cells. Percentage of specific cytotoxicity was calculated as:
- % ⁇ ⁇ cytotoxicity ( 100 ) ⁇ ( mean ⁇ ⁇ cpm ⁇ ⁇ test ⁇ ⁇ release - mean ⁇ ⁇ cpm ⁇ ⁇ spontaneous ⁇ ⁇ release ) ( mean ⁇ ⁇ cpm ⁇ ⁇ maximum ⁇ ⁇ release - mean ⁇ ⁇ cpm ⁇ ⁇ spontaneous ⁇ ⁇ release )
- Immunoblot and enzyme linked immunosorbent assays were used as substrate for an immunoblot assay as described in Yamamoto et al., 1993.
- FIV Pet from tissue culture fluid of infected cells was clarified by low speed centrifugation (2000 rpm for 45 min), concentrated by ultracentrifugation (16,000 rpm for 2 hr), and purified by ultracentrifugation on a 10/50% (w/v) continuous sucrose gradient. The virus purified by this procedure was used as the substrate for the immunoblot assay.
- Virus blot strips were prepared by solubilizing virus in 0.1% SDS, followed by electrophoresis on 10% SDS-polyacrylamide gel and electrophoretic transfer onto nitrocellulose membrane. Serum samples from vaccinated cats were diluted to 1:50 in Buffer 3 (0.15 M sodium chloride, 0.001 M editic acid, 0.05 M TRIS base, 0.05% Tween 20, and 0.1% bovine serum albumin) and incubated with virus blot strips in separate wells of immunoblot plate for 18 hrs at 37° C.
- Buffer 3 (0.15 M sodium chloride, 0.001 M editic acid, 0.05 M TRIS base, 0.05% Tween 20, and 0.1% bovine serum albumin
- the blot strips were washed individually with wash solution (0.15 M NaCl and 0.05% Tween 20 in deionized H 2 O), incubated with biotinylated anti-cat IgG (Vector Laboratories, Burlingame, Calif.) for 1 hr at 37° C., and washed three times with wash solution. The strips were then incubated individually with horseradish peroxidase conjugated Streptavidin (Vector Laboratories) for 30 min. After extensive washing, each strip was incubated with a fresh substrate solution (0.05% diaminobenzidine, 400 ⁇ g/ml NiCl 2 , and 0.01% H 2 O 2 in 0.1 M Tris buffer, pH 7.4) at room temperature.
- wash solution 0.15 M NaCl and 0.05% Tween 20 in deionized H 2 O
- biotinylated anti-cat IgG Vector Laboratories, Burlingame, Calif.
- the reaction was stopped with excess distilled H 2 O upon establishment of visible bands, and the strips were blot dried.
- the molecular weights of the bands on the immunoblots were then determined by comparing them with the migration distance of the molecular weights standards on a strip previously stained with amido black. Positive and negative control serum were included in each immunoblot analysis as internal controls for diagnostic evaluation.
- the viral antigen-specific ELISA has been previously described (Yamamoto et al., 1991a; Yamamoto et al., 1993). Sucrose gradient purified FIV Pet and surface envelope (SU) and transmembrane (TM) peptides of both conserved (C) and variable (V) regions of FIV Pet were coated on 96 well Immunolon plates (Dynatech Laboratories, Inc., Chantilly, Va.) at 250 ng/well with bicarbonate buffer (pH 9.6) for 12 to 18 hours at 37° C. and were used as substrates for ELISA.
- SU Sucrose gradient purified FIV Pet and surface envelope
- TM transmembrane
- C conserved
- V variable
- the amino acid sequence of the SU-V3-2 peptide is: Gly Ser Trp Phe Arg Ala Ile Ser Ser Trp Lys Gln Arg Asn Arg Trp Glu Trp Arg Pro Asp Phe (SEQ ID NO. 1); and the amino acid sequence of the TM-C1 peptide is: Gln Glu Leu Gly Cys Asn Gln Asn Gln Phe Phe Cys Lys Ile (SEQ ID NO: 2).
- the synthetic peptides were synthesized on a Biosearch 9500 peptide synthesizer (Biosearch, San Rafael, Calif.) using FMOC peptide synthesis chemistry (Magazine et al., 1988). Purity of the synthesized peptides was determined by the presence of a single peak on a reversed-phase high-performance liquid chromatography and confirmed by amino acid sequence analysis performed on the peak sample.
- the peptide coated plates were washed once with Buffer 3 immediately prior to use.
- the serum samples were diluted at 1:200 in Buffer 3 and incubated in the FIV antigen coated wells for 1 hr at 37° C., then washed 6 times.
- the wells were washed with wash solution, incubated with biotinylated anti-cat IgG (Vector Laboratories, Burlingame, Calif.) for 1 hr at 37° C., washed 6-times, and incubated with horseradish peroxidase conjugated Streptavidin (Vector Laboratories) for 1 hr at 37° C.
- PCR Polymerase Chain Reaction
- the approximate amount of proviral DNA per cell was determined by semi-quantitative PCR, in which varying dilutions of DNA extracted from a known number of cells are made. For example, if 10 5 cells are used for DNA extraction, then a 10 ⁇ 5 dilution of the DNA preparation will approximately correspond to the DNA present in a single cell. PCR was performed on these varying DNA dilutions and the final dilution that gave a positive PCR result is considered the end-point dilution. The number of cells corresponding to the end-point dilution is used to determine the percentage of cells infected with virus in a given cell preparation according to the following formula:
- RT Reverse transcriptase assay.
- the presence of RNA-dependent DNA polymerase (RT) was assayed in cell culture supernatants essentially as described by Rey et al.
- the RT assay for detecting FIV used poly(rA)-oligo(dT 12-18 ) as an exogenous template primer, four different deoxyribonucleotide triphosphates, 20 mM KCl with Mg ++ as divalent cation and 5 ⁇ Ci [ 3 H]-labeled thymidine triphosphate (TTP) per sample.
- Viral neutralization assay A strategy for developing strain- and subtype-specific VN assays has been described (Okada et al., 1994). Serial dilutions of heat-inactivated sera were incubated with 100 TCID 50 of each FIV strain for 45 minutes at 37° C. in a 24-well plate prior to addition of feline peripheral blood mononuclear cells (PBMC) (4 ⁇ 10 5 cells/ml) or FIV-susceptible FeT-1C cells (2 ⁇ 10 5 cells/ml).
- PBMC peripheral blood mononuclear cells
- FIV-susceptible FeT-1C cells 2 ⁇ 10 5 cells/ml
- the cells were washed once with Hank's balanced salt solution to remove residual virus from the culture and then the cells were resuspended in fresh culture media (RPMI-1640 containing 10% heat-inactivated fetal calf serum, 10 mM HEPES buffer, 50 ⁇ g/ml gentamicin, 5 ⁇ 10 ⁇ 5 M 2-mercaptoethanol, and 100 Units/ml human recombinant IL-2).
- Virus infection of cells was monitored by Mg ++ -dependent RT assays of the culture fluids harvested on 9, 12, 15, and 18 days of culture. Sera were considered positive for VN antibodies when RT activity was ⁇ 25% of infected control cultures consisting of SPF serum.
- a novel interleukin-2 (IL-2) dependent feline T-cell line designated as FeT-1C, which is a mother line of an IL-2-dependent FeT-1M clone, was used to establish individual cell lines chronically infected with either FIV Pet , FIV Dix , FIV UK8 , FIV Bang , FIV Aom2 , or FIV Shi .
- the FeT-1M clone also referred to as FIV-Fet1M
- FL-4 also described in U.S. Pat. No. 5,275,813
- the FeT-1C cell line is highly infectable with different isolates from FIV subtypes A, B, and D. Long-term passaging of the FeT-1C cell line decreases its infectability, especially to FIV subtype D; therefore, the passage number should be less than about 35 passages for optimal FIV infection rates or for its use in VN assays. Semi-quantitative PCR and viral core antigen analyses indicated that all the cell lines exposed to FIV were significantly infected with individual FIV strains.
- An IL-2 independent feline cell line susceptible to FIV infection has also been developed from FeT-1C cells.
- This cell line designated as FeT-J
- FeT-J can be infected with FIV by co-culture using FIV infected media or cells.
- an FIV Bang -infected FeT-1C cell line was co-cultured in the absence of IL-2 with uninfected FeT-J cells to establish an IL-2-independent FIV Bang -infected FeT-J cell line (designated as Bang/FeT-J).
- Bang/FeT-1C cells were combined with uninfected FeT-J cells at a ratio of from about 2:1 to about 10:1 (infected:uninfected).
- the cell mix was cultured in media in the absence of IL-2 for several days and the FeT-1C cells were allowed to die off. The remaining cells consisted of FIV Bang -infected FeT-J cells.
- FIV-infected FeT-1C cells can be used to infect FeT-J cells and establish IL-2-independent FeT-J cell lines infected with different FIV subtypes.
- the co-cultivation method with FIV infected FeT-1C cells resulted in IL-2-independent FeT-J cell lines producing moderate to high levels of different FIV subtypes.
- the FeT-1C cell line was also infected with FIV Shi and extensively passaged to produce an IL-2-dependent cell line designated as Shi/FeT-1C.
- the Shi/FeT-1C cell line was later co-cultured with FeT-J in the absence of IL-2 and the resulting IL-2-independent FIV Shi -infected cell line was designated as Shi/FeT-J.
- the IL-2-independent Shi/FeT-J cell line produces higher levels of FIV Shi than IL-2-dependent Shi/FeT-1C cell line ( FIG. 1 ).
- the development of a FeT-J cell line infected with FIV Bang was also performed without the use of the FeT-1C cell line.
- the FeT-J cell line was directly infected with cell-free FIV Bang inoculum and extensively passaged without IL-2.
- the resulting IL-2-independent FIV Bang producer cell line was designated Bang/FeT-J.
- the Bang/FeT-J cell line produced higher levels of FIV Bang than the IL-2-dependent Bang/FeT-1C cell line which was developed by infecting FeT-1C cell line with FIV Bang ( FIG. 1 ).
- FIV-infected cells were removed from supernatants by centrifugation, inactivated, and used as vaccine. Similarly, whole FIV virus were pelleted from infected cell-free supernatant by ultracentrifugation and inactivated. Both infected cells and virus were inactivated by treatment with 1.25% paraformaldehyde for 24 hours at 5° C., followed by extensive washing or dialysis against PBS, respectively. This method efficiently inactivates FIV without loss of immunogenicity.
- FIV immunogens produced according to the subject method are highly effective for inducing protective immunity (Yamamoto et al., 1993; Yamamoto et al., 1991a; Yamamoto et al., 1991b). It is contemplated that attenuated viral isolates could also be used in the vaccine compositions of the subject invention.
- FIV Shi -infected FeT-1C cell line was superinfected with the FIV Pet strain to produce a single cell line infected with multiple subtypes of FIV (i.e., a multi-subtype A/D FeT-1C cell line)
- FIV Shi proviral levels decreased from 50% to less than 5%
- FIV Pet proviral levels concomitantly increased to about 50%.
- the maintenance of a single cell line infected with multiple subtypes of FIV for use as an FIV vaccine is not the preferred embodiment of the subject invention.
- vaccine compositions were developed from two individual cell lines, each line being infected with a different FIV subtype.
- the dual-subtype FIV vaccine composition comprised a combination of an FIV subtype A-infected cell line (Pet/FL-4) with an FIV subtype D-infected cell line (Shi/FeT-1C).
- the A-subtype and D-subtype infected cell lines were inactivated as described, combined in equal cell numbers (2.5 ⁇ 10 7 cells each in 250 ⁇ g of MDP) and used to immunize cats.
- the dual-subtype vaccinated cats (Pet/FL-4 cells and Shi/FeT-1C cells) developed FIV antibodies specific for the viral core protein p25 (also call FIV p28) after the second immunization ( FIG. 2 ). Higher antibody titers to other viral antigens were demonstrated after the third to fourth immunization.
- VN antibodies to FIV Pet developed after the second immunization
- VN antibodies to FIV Shi developed after the fourth immunization (Table 4).
- CTL responses to FIV Pet and FIV Shi were detected as early as the third immunization in all cats tested (Table 3) and stronger CTL responses to both strains were developed after the fourth immunization.
- the cats immunized with inactivated Shi/FeT-1C cells developed FIV antibodies specific for the viral core protein p25 after the second immunization and antibodies to other viral antigens after the third immunization ( FIG. 2 ).
- VN antibodies to FIV Shi in these cats developed after the fourth immunization, whereas VN antibodies to FIV Pet were not detected over the course of the immunizations.
- Both of the Shi/FeT-1C vaccinated cats developed CTL responses to FIV Shi only after the fourth immunization but did not develop CTL responses to FIV Pet , even after the fourth immunization (Table 3).
- the vaccine composition of the subject invention comprises a triple-subtype FIV vaccine prepared from three cell lines, each cell line having been infected with a viral strain from a different FIV subtype (A or B or D).
- a triple-subtype FIV vaccine prepared from three cell lines, each cell line having been infected with a viral strain from a different FIV subtype (A or B or D).
- Three specific pathogen free cats were immunized with a triple-subtype (FIV Pet +FIV Bang +FIV Shi ) vaccine.
- Other cats were immunized with single-subtype FIV Bang vaccines to evaluate the immunogenicity of macrophage-tropic FIV Bang as a component of the vaccine.
- the three SPF cats immunized with a combination of inactivated Pet/FL-4, inactivated Bang/FeT-J, and inactivated Shi/FeT-1C cells developed FIV antibodies specific for the viral core protein p25 and to other viral antigens, including FIV SU and TM envelope protein, after the second immunization ( FIGS. 3 , 4 , 5 ).
- VN antibodies to FIV Pet , FIV Bang and FIV Shi developed in the majority of cats soon after the second immunization and in all cats by the third immunization (Table 5).
- the triple-subtype vaccine induced a broad CTL response and more rapid and higher VN and SU-envelope antibody titers than the single-subtype vaccine.
- VN Virus neutralization
- An assay for VN antibodies to FIV was also developed using the FeT-1C cells of the subject invention. Serum from FIV Pet -infected cats and SPF cats vaccinated with inactivated Pet/FL-4 cells or inactivated FIV Pet virus were tested for VN antibody titer using either FeT-1C cells or PBMC according to the VN assay method described herein. Sera from two SPF cats which were unvaccinated and FIV uninfected were used as control sera. Sera from vaccinated and FIV infected cats had a high VN antibody titer of 1000 or greater, whereas sera from unvaccinated SPF cats had no detectable VN antibody titer.
- FeT-1C-based VN assay gives VN antibody titer results comparable to those obtained using primary PBMC from cats (Table 6). This finding demonstrates that VN antibody titers in a VN assay using FeT-1C cells correlates with those results obtained with a VN assay using PBMC. Therefore, FeT-1C cells can be advantageously used in place of PBMC in the standard VN assay for FIV since FeT-1C cells can be infected with all the FIV subtypes and can be readily propagated in tissue culture.
- VN titers assayed on FeT-1C and PBMC VN titers Serum source FeT-1C PBMC Vaccinated 1 5000 5000 Vaccinated 1 >1000 >1000 Infected 2 1000 1000 Infected 2 >1000 >1000 Uninfected cell ⁇ 10 ⁇ 10 immunized 3 Uninfected cell ⁇ 10 ⁇ 10 immunized 3 1 Sera from inactivated Pet/FL-4 cell vaccinated cats 2 Sera from FIV pet infected cats 3 Sera from inactivated uninfected FeT-J immunized cats
- FIV Pet a subtype A strain, was significantly cross-neutralized by antisera from cats infected with FIV Dix .
- FIV Pet differs from FIV Dix by approximately 9% at surface envelope glycoprotein (Env) regions.
- Antisera from cats infected with subtype B and D strains only cross-neutralized other FIV strains within the homologous subtype. Further, antisera from cats infected with FIV UK8 neutralized FIV Bang but did not neutralize FIV strains within subtype A.
- FIV UK8 is classified as subtype A (Sodora et al., 1994; Rigby et al., 1993; Kakinuma et al., 1995), these results suggest that antisera to FIV UK8 recognizes subtype B strains, but does not recognize subtype A strains, and may explain why inactivated FIV Pet vaccines were ineffective against FIV UK8 and FIV Shi (Johnson et al., 1994). Thus, a loose correlation exists between genotype and immunotype. Although genotypic analyses allow for FIV strain classification, cross-neutralization antibody studies reflect the immunogenicity of FIV strains, which is an important parameter in broad-range humoral protection elicited by vaccines.
- FIV strains obtained from infected FeT-1C and infected FeT-J cell lines were compared to those FIV strains obtained from primary PBMC (Table 8).
- Two FIV isolates, FIV UK8 and FIV Bang are both equally lymphotropic and macrophage-tropic, whereas FIV Shi is highly lymphotropic.
- FIV Pet was more lymphotropic than macrophage-tropic and its cell tropism was not significantly affected by its cell source.
- the macrophage-tropism of FIV Bang was not affected by the cell source of the virus.
- the virus grown in FeT-1C cells can be used as inoculum for VN assays and also as an in vivo inoculum for studies to evaluate therapeutic and prophylactic approaches.
- TCID 50 a FeT- Alveolar Primary FIV (Subtype) FIV Source 1C PBMC Macrophage Microglia Petaluma (A) PBMC 10 4 10 4 10 2 ND Petaluma (A) FeT-1C b 10 4 10 4 10 1 ND Petaluma (A) FL-4 4 10 4 10 4 10 1 ND Dixon (A) FeT-1C 10 4 10 3 10 1 ND UK8 (A) PBMC 10 2 10 3 10 3 ND UK8 (A) FeT-1C 10 3 10 3 10 3 ND Bangston (B) PBMC 10 3 10 3 10 3 10 3 10 2 Bangston (B) FeT-1C b 10 3 10 3 10 3 10 2 Bangston (B) FeT-J b 10 3 10 3 10 3 10 2 Shizuoka (D) PBMC 10 2 10 3 ⁇ 1 ND Shizuoka (D) FeT-1C b 10 3 10 3 ⁇ 1 ND Shizuoka (D) FeT-1C b 10 3 10 3
Abstract
The subject invention pertains to novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multi-subtype FIV vaccine. Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Methods for vaccinating cats with the subject vaccine compositions are also described. Cats vaccinated according to the methods and compositions of the subject invention exhibit protective humoral and cellular immune responses to FIV when challenged with homologous or heterologous strains of FIV. The subject invention also pertains to novel feline cell lines that are susceptible to infection by FIV and their methods of use.
Description
- This application is a continuation of U.S. application Ser. No. 10/408,701, filed Apr. 7, 2003, which is a continuation of U.S. application Ser. No. 09/707,532, filed Nov. 7, 2000, now, U.S. Pat. No. 6,544,528, which is a continuation U.S. application Ser. No. 09/025,610, filed Feb. 18, 1998, now, U.S. Pat. No. 6,254,872, which is a continuation of International Application No. PCT/US96/13580, filed Aug. 23, 1996 and this application is a continuation-in-part of U.S. application Ser. No. 09/512,746, filed Oct. 1, 1997, now U.S. Pat. No. 6,447,993, which is a continuation of U.S. application Ser. No. 08/519,386, filed Aug. 25, 1995, now abandoned, the disclosure of each of which is hereby incorporated by reference herein in its entirety, including any brief summary, detailed descriptions of the invention, examples, claims, abstract, figures, tables, nucleic acid sequences, and amino acid sequences.
- The subject invention was made with government support under a research project supported by National Institutes of Health Grant No. NIH AI30904. The government has certain rights in this invention.
- Domestic cats are subject to infection by several retroviruses, including feline leukemia virus (FeLV), feline sarcoma virus (FeSV), endogenous type C oncoronavirus (RD-114), and feline syncytia-forming virus (FeSFV). Of these, FeLV is the most significant pathogen, causing diverse symptoms including lymphoreticular and myeloid neoplasms, anemias, immune-mediated disorders, and an immunodeficiency syndrome that is similar to human acquired immune deficiency syndrome (AIDS). Recently, a particular replication-defective FeLV mutant, designated FeLV-AIDS, has been more particularly associated with immunosuppressive properties.
- The discovery of feline T-lymphotropic lentivirus (now designated as feline immunodeficiency virus, FIV) was first reported in Pedersen et al. (1987). Characteristics of FIV have been reported in Yamamoto et al. (1988a); Yamamoto et al. (1988b); and Ackley et al. (1990). Seroepidemiologic data have shown that infection by FIV is indigenous to domestic and wild felines throughout the world. A wide variety of symptoms are associated with infection by FIV, including abortion, alopecia, anemia, conjunctivitis, chronic rhinitis, enteritis, gingivitis, hematochezia, neurologic abnormalities, periodontitis, and seborrheic dermatitis. The immunologic hallmark of domestic cats infected with FIV is a chronic and progressive depletion of feline CD4+ peripheral blood lymphocytes, a reduction in the CD4:CD8 cell ratio and, in some cases, an increase in CD8-bearing lymphocytes. Based on molecular, biochemical and immunopathologic characteristics, FIV infection of cats is now considered to be a better feline AIDS model than FeLV-FAIDS.
- Cloning and sequence analysis of FIV has been reported in Olmsted et al. (1989a); Olmsted et al. (1989b); and Talbott et al. (1989). Hosie and Jarret (1990) described the serological response of cats infected with FIV. FIV virus subtypes can be classified according to immunotype based on the level of cross-neutralizing antibodies elicited by each strain (Murphy and Kingsbury, 1990). Recently, viruses have been classified into subtypes according to genotype based on nucleotide sequence homology. Although HIV and FIV subtyping is based on genotype (Sodora et al., 1994; Rigby et al., 1993; and Louwagie et al., 1993), little is known about the correlation between the genotype and immunotype of subtypes. FIV viral isolates are currently classified into four FIV subtypes: A, B, C and D. (Kakinuma et al., 1995). Infectious isolates and infectious molecular clones have been described for all FIV subtypes except for subtype C (Sodora et al., 1994). Subtype C FIV has only been identified from cellular DNA of cats from Canada (Sodora et al., 1994; Rigby et al., 1993; Kakinuma et al., 1995).
- A major difficulty in developing an FIV vaccine has been in identifying a vaccine approach that is effective against a broad range of FIV strains including field isolates from different subtypes or clades. Vaccine prophylaxis for FIV has been attained against homologous and slightly heterologous strains using a single-strain vaccine, but not against challenge with moderate to greatly heterologous strains (Johnson et al., 1994; Yamamoto et al., 1993). Thus, there remains a need for a vaccine that protects across multiple FIV subtypes.
- The subject invention concerns a vaccine that elicits a broad range of protective immunity against FIV infections in a host animal. Specifically, the subject invention concerns a multi-subtype FIV vaccine that is prepared using cell-free viral isolates from different FIV subtypes, or a combination of cell lines each infected with a different prototype FIV virus from a different subtype. Cats vaccinated with the FIV vaccines of the subject invention develop humoral and cellular immune responses to homologous and heterologous FIV strains.
- The subject invention also concerns novel feline cell lines that are susceptible to infection by multiple FIV subtypes. The cell lines of the subject invention are useful for propagating and producing multiple FIV subtypes, as well as for use in FIV vaccines according to the methods of the subject invention. In addition, the cell lines can also be used in place of feline peripheral blood mononuclear cells (PBMC) in FIV viral neutralization assays of feline antisera.
-
FIG. 1 shows the reverse transcriptase (RT) levels of FIVBang and FIVShi produced after infecting FeT-1C and FeT-J cell lines with these FIV strains. -
FIG. 2 shows the immunoreaction of anti-FIV antibodies from dual-subtype vaccinated cats with FIV proteins as detected by immunoblot. The number over each blot represent the number of vaccinations received by the animal when the sera was tested. -
FIG. 3 shows the immunoreaction of anti-FIV antibodies from triple-subtype vaccinated cats with FIV proteins as detected by immunoblot. The number over each blot represent the number of vaccinations received by the animal when the sera was tested. -
FIG. 4 shows the immunoreactivity of anti-FIV antibodies from triple-subtype vaccinated cats with FIV SU-V3-2 peptide as detected by ELISA. -
FIG. 5 shows the immunoreactivity of anti-FIV antibodies from triple-subtype vaccinated cats with FIV TM-C1 peptide as detected by ELISA. -
FIG. 6 shows cross-neutralizing antibody titers of sera from cats infected with either FIVPet (AP), FIVDix (AD), FIVUK8 (AU), FIVBang (BB), FIVAom1 (BA), and FIVShi(DS). Sera at pre-infection (column 1), 6 months post-infection (column 2), and 12 months post-infection (column 3) were tested against subtype A FIVPet, subtype B FIVBang, and subtype D FIVShi in the FeT-1C-cell line. At least three cats per each strain were tested and results show VN titer from a representative cat from each strain. Similar results were obtained using primary PBMC for VN assay. - SEQ ID NO: 1 is an amino acid sequence of an FIV surface envelope peptide designated as SV-V3-2.
- SEQ ID NO: 2 is an amino acid sequence of an FIV transmembrane peptide designated as TM-C1.
- SEQ ID NO: 3 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 4 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 5 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 6 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 7 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 8 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 9 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 10 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 11 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 12 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 13 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 14 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 15 is a nucleotide sequence of an FIV PCR primer.
- SEQ ID NO: 16 is a nucleotide sequence of an FIV PCR primer.
- The subject invention concerns novel methods and vaccine compositions useful for inducing protective immunity to FIV infection in a susceptible host animal. The vaccine compositions described herein, when administered to a host animal, induce protective humoral and cellular immune responses against infection by homologous and heterologous strains of FIV. The vaccine compositions may comprise either cell-free FIV viral isolates or FIV-infected cell lines. In a preferred embodiment, the vaccine composition of the subject invention comprises FIV strains from two different FIV subtypes. Preferably, the vaccine composition comprises three FIV strains, each strain from a different FIV subtype. More preferably, at least one FIV strain from each of FIV subtype A, subtype B and subtype D is included in the vaccine composition.
- In a specific embodiment, the vaccine composition comprises FIVPet- and FIVShi-infected cell lines. In another embodiment, the vaccine composition comprises FIVPet-, FIVBang-, and FIVShi-infected cell lines. The use of other FIV strains representative of all or a portion of FIV subtypes is specifically contemplated by the subject invention. For example, FIVDix or FIVUK8 could be included in the vaccine compositions in addition to or in place of FIVPet for purposes of providing an FIV subtype A prototype virus. Similar additions or substitutions with other FIV strains could be made for FIV subtype B and D prototype viruses.
- As described herein, the vaccine compositions of the subject invention may comprise cell-free whole FIV virus, or portions of the virus, FIV proteins and polypeptides, as well as FIV-infected cell lines, or a combination of cell-free virus and infected cell lines. Vaccine compositions comprising FIV-infected cell lines may comprise multiple cell lines, each infected with a different FIV subtype. The vaccine compositions of the subject invention also encompass recombinant viral vector-based FIV constructs that may comprise, for example, FIV env, gag/pro, or env-gag/pro. Any suitable viral vector that can be used to prepare recombinant vector/FIV constructs is contemplated for use with the subject invention. For example, viral vectors derived from adenovirus, avipox, feline herpesvirus, vaccinia, canarypox, entomopox, swinepox and others known in the art can be used with the compositions and methods of the present invention. Recombinant polynucleotide vectors that encode and express FIV components can be constructed using standard genetic engineering techniques known in the art. In addition, the various vaccine compositions described herein can be used separately and in combination with each other. For example, primary immunizations of an animal may use recombinant vector-based FIV constructs, having single or multiple subtype components, followed by secondary boosts with vaccine compositions comprising inactivated FIV-infected cell lines. Other immunization protocols with the vaccine compositions of the invention are apparent to persons skilled in the art and are contemplated within the scope of the present invention.
- The multi-subtype FIV vaccines specifically described herein were tested for immunogenicity and efficacy in cats. Specific pathogen free (SPF) cats vaccinated with the subject vaccine compositions were monitored for humoral and cellular immune responses before and after challenge with homologous and heterologous FIV strains. Humoral responses were monitored by measuring viral neutralizing (VN) antibody activity and cellular responses were monitored by measuring cytotoxic T lymphocyte (CTL) activity. Sera and immunocytes from vaccinated cats were tested in vitro for VN and CTL activities, respectively, against homologous and heterologous FIV strains, and demonstrated that the vaccines can elicit broad-range protection from FIV infection. According to the teachings of the subject invention, by combining prototype virus isolates from different FIV subtypes, or by combining individual cells infected with prototype virus of different subtypes, an effective multi-subtype FIV vaccine can be produced.
- All FIV strains, in addition to those specifically exemplified herein, are contemplated for use with the subject invention. A number of FIV isolates have been described in the literature and are known to those skilled in the art. FIVPet has been described in U.S. Pat. No. 5,037,753. Other FIV isolates which have been described can be readily isolated from infected cats by persons of ordinary skill in the art using standard techniques. Methods for isolating and culturing FIV are described in U.S. Pat. Nos. 5,037,753 and 5,118,602, which are herein incorporated by reference.
- The novel cell lines exemplified herein can be used in the vaccine methods and compositions of the present invention. Other cells or cell lines that are susceptible to infection by FIV strains, including peripheral blood mononuclear cells, are also contemplated for use with the present invention.
- Natural, recombinant or synthetic polypeptides of FIV viral proteins, and peptide fragments thereof, can also be used as vaccine compositions according to the subject methods. In a preferred embodiment, FIV polypeptides derived from multiple FIV subtypes are combined in a vaccine composition and are used to vaccinate a host animal. For example, polypeptides based on the FIV envelope glycoprotein from at least two prototype FIV strains from different subtypes can be combined in the vaccine. The polypeptides may be homologous to one strain or may comprise “hybrid” or “chimeric” polypeptides whose amino acid sequence is derived from joining or linking polypeptides from at least two distinct FIV subtypes. Procedures for preparing FIV polypeptides are well known in the art. For example, FIV polypeptides can be synthesized using solid-phase synthesis methods (Merrifield, 1963). FIV polypeptides can also be produced using recombinant DNA techniques wherein a polynucleotide molecule encoding an FIV protein or peptide is expressed in a host cell, such as bacteria, yeast, or mammalian cell lines, and the expressed protein purified using standard techniques of the art.
- The present invention also concerns novel feline T-cell lines that are susceptible to infection by FIV. Both interleukin-2 (IL-2) dependent and independent cells are specifically exemplified. The cell lines designated as FeT-1C and FeT-J are described herein. The FeT-1C cell line is IL-2 dependent, whereas the FeT-J cell line is IL-2 independent. The cell lines of the subject invention are useful for providing a vehicle for FIV immunization of cats, as well as for propagating and producing FIV viral strains in vitro. Both the IL-2-dependent FeT-1C and IL-2-independent FeT-J uninfected cell lines were tested over 20 times for reverse transcriptase (RT) activity in culture fluids and for FIV proviral sequence by PCR and were confirmed negative for FIV. FeT-J cell line was highly infectable with all of the FIV strains tested, including FIVShi, FIVDix, FIVUK8, FIVPet and FIVBang but was more difficult to directly infect with FIVShi.
- The subject invention further concerns cellular products produced by the cell lines of the present invention. The cellular products can be isolated and detected using procedures known to the skilled artisan. Antibodies to the cell lines can also be produced using known methods and are contemplated by the subject invention.
- The FIV uninfected cell lines designated as FeT-1C (ATCC Accession No. CRL 11968) and as FeT-J (ATCC Accession No. CRL 11967) were both deposited with the American Type Culture Collection, Rockville, Md. on Aug. 24, 1995. FIVBang-(ATCC Accession No. 11975) and FIVShi-(ATCC Accession No. 11976) infected cell lines were deposited with the American Type Culture Collection on Aug. 25, 1995.
- The subject cultures have been deposited under conditions that assure that access to the culture will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 CFR 1.14 and 35 U.S.C. 122. The deposit will be available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.
- Further, the subject culture deposit will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of Microorganisms, i.e., it will be stored with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposit, and in any case, for a period of at least thirty (30) years after the date of deposit or for the enforceable life of any patent which may issue disclosing the culture. The depositor acknowledges the duty to replace the deposit should the depository be unable to furnish a sample when requested, due to the condition of the deposit. All restrictions on the availability to the public of the subject culture deposit will be irrevocably removed upon the granting of a patent disclosing it.
- According to the methods of the subject invention, the FIV vaccine compositions described herein are administered to susceptible hosts, typically domestic cats, in an effective amount and manner to induce protective immunity against subsequent challenge or infection of the host by FIV. The vaccines are typically administered parenterally, by injection, for example, either subcutaneously, intraperitoneally, or intramuscularly. Other suitable modes of administration include oral or nasal administration. Usually, the vaccines are administered to a host at least two times, with an interval of one or more weeks between each administration. However, other regimens for the initial and booster administrations of the vaccine are contemplated, and may depend on the judgment of the practitioner and the particular host animal being treated.
- The vaccine compositions of the subject invention can be prepared by procedures well known in the art. For example, the vaccines are typically prepared as injectables, e.g., liquid solutions or suspensions. The vaccines are administered in a manner that is compatible with dosage formulation, and in such amount as will be therapeutically effective and immunogenic in the recipient. The optimal dosages and administration patterns for a particular vaccine formulation can be readily determined by a person skilled in the art.
- Virus and cells in a vaccine formulation may be inactivated or attenuated using methods known in the art. For example, whole virus and infected cells can be inactivated or attenuated. by exposure to paraformaldehyde, formalin, phenol, UV light, elevated temperature and the like. The amount of cell-free whole FIV virus in a vaccine dose will usually be in the range from about 0.1 mg to about 5 mg, and more usually being from about 0.2 mg to about 2 mg. The dosage for vaccine formulations comprising FIV-infected cell lines will usually contain from about 106 to about 108 cells per dose, and more usually from about 5×106 to about 7.5×107 cells per dose.
- Virus or cells were typically combined with an adjuvant just prior to administration. Adjuvants used in the vaccine formulations typically were either threonyl muramyl dipeptide (MDP) (Byars et al., 1987) or a combination of Freud's complete and incomplete adjuvants. A variety of other adjuvants suitable for use with the methods and vaccines of the subject invention, such as alum, are well known in the art and are contemplated for use with the subject invention.
- The subject invention further concerns a novel method for assaying for virus neutralizing (VN) antibodies in a sample using the uninfected cell lines of the present invention. Unlike PBMC which expire after a limited number of passages and do not propagate as readily as FeT-1C or FeT-J cells, the FeT-1C and FeT-J cells are an established cell line and can be readily cryopreserved for future use. Results obtained from VN assays using FeT-1C cells are more highly reproducible than VN assays using PBMC because PBMC from different SPF cats have individual variability in cell growth rate and FIV infectability. Further, PBMC for VN assays have to be obtained from SPF cats which require germ-free housing and maintenance in order to eliminate possible in vivo infection which may affect an in vitro VN assay using PBMC. Thus, a feline cell line such as FeT-1C which can be readily infected with FIV of different subtypes can be advantageously substituted for PBMC in VN assays.
- The following abbreviations of FIV strains are used herein:
-
Strain (subtype) Abbreviation Petaluma (A) FIVPet Dixon (A) FIVDix UK8 (A) FIVUK8 Bangston (B) FIVBang Aomori-1 (B) FIVAom1 Aomori-2 (B) FIVAom2 Shizuoka (D) FIVShi - All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety to the extent they are not inconsistent with the explicit teachings of this specification.
- Cell cultures. All suspension cell lines were cultured in RPMI 1640 containing 10% heat-inactivated fetal calf serum (FCS). 10 mM HEPES (N-2-hydroxyethylpiperazine-n′-2-ethane sulfonic acid), 2 mM L-glutamine, 50 μg/ml gentamicin and 5×10−5M 2-mercaptoethanol. IL-2-dependent cells were supplemented with 100 U/ml of recombinant human IL-2 (Cetus Corporation, Emeryville, Calif.). The suspension cells were passaged at a cell concentration of 0.5-4×106 cells/ml and recultured in fresh culture media twice a week. All monolayer cells were passaged twice a week at an initial cell concentration of 2×106 cells/ml. The tissue culture fluids (TCF) from FIV-infected cells were harvested twice a week, spun at 3000 rpm for 1 hour to remove residual cells, and stored at −20° C., or at −70° C. for those TCF scheduled to be used immediately upon testing. FIV-susceptible cells (1×106 cells/ml) were infected with FIV having a reverse transcriptase (RT) activity of about 30,000 cpm/ml.
- FIV purification. Tissue culture fluids from FIV-infected cell lines were individually centrifuged at 2000 to 3000 rpm for 1 hr to remove cells. Virus in the TCF was pelleted by ultracentrifugation at 16,000 rpm for 2 hours, and purified by ultracentrifugation first on a 10/50% (w/v) discontinuous sucrose gradient and then on a 10/50% continuous sucrose gradient (Pederson et al., 1987; Yamamoto et al., 1988). Each of the viral isolates was inactivated with 1.25% sterile paraformaldehyde (0.22 μm sterile filtered) for 18 hr and subsequently extensively dialyzed against sterile PBS. The inactivated viruses were diluted to a concentration of 500 μg/ml with sterile PBS and 250 μg/0.5 ml of each strain was placed in sterile microfuge tube and stored at −70° C. The inactivated FIV strains were thawed at room temperature and 250 μg of inactivated virus in 0.5 ml sterile PBS was combined with 0.5 ml of adjuvant just prior to immunization. FIV-infected cell lines were separately inactivated with 1.25% sterile paraformaldehyde for 18 hr, washed 3 times with sterile PBS, resuspended in fresh sterile PBS at concentration of about 5.0×107 cells/ml in sterile tubes and stored at 4° C. Typically, about 2.5×107 inactivated infected cells in 0.5 ml sterile PBS were combined with 0.5 ml of adjuvant just prior to immunization. 250 μg/0.5 ml of threonyl muramyl dipeptide (MDP MF75.2 adjuvant; Chiron Corporation, Emeryville, Calif.) was used as an adjuvant.
- CTL assay. Peripheral blood mononuclear cells (PBMC) were stimulated with Concanavalin A (Con A) for 3 days prior to infection with FIV for 10 days (Song et al., 1992). These cells served as target cells for the CTL assay. CTL activity was generated by co-culturing Con A-stimulated PBMC with autologous UV- and radiation inactivated FIV-infected PBMC for 5 days. These cells served as the stimulated effector cells. On the assay day, target cells were labeled with 50 μCi of Na51CrO4 for 1 to 3 hours, washed 3 times, and then a fixed number of labeled target cells (5×104 cells/well) were added to microtiter plates. Effector cells were added in triplicate at various effector/target cell ratios (i.e., 100:1, 50:1, and 10:1). Plates were centrifuged for 1 minute at 400 rpm and incubated at 37° C. for 4 hours. Control 51Cr-labeled target cells were lysed with detergent to obtain maximal release values. Supernatants from the test sample wells were collected and radiation was quantified using a gamma counter. Spontaneous release was determined by incubating 51Cr-labeled target cells in the absence of effector cells. Percentage of specific cytotoxicity was calculated as:
-
- Immunoblot and enzyme linked immunosorbent assays (ELISA). Sucrose gradient purified virus was used as substrate for an immunoblot assay as described in Yamamoto et al., 1993. FIVPet from tissue culture fluid of infected cells was clarified by low speed centrifugation (2000 rpm for 45 min), concentrated by ultracentrifugation (16,000 rpm for 2 hr), and purified by ultracentrifugation on a 10/50% (w/v) continuous sucrose gradient. The virus purified by this procedure was used as the substrate for the immunoblot assay.
- A modification of an immunoblot technique previously described was used (Yamamoto et al., 1991a). Virus blot strips were prepared by solubilizing virus in 0.1% SDS, followed by electrophoresis on 10% SDS-polyacrylamide gel and electrophoretic transfer onto nitrocellulose membrane. Serum samples from vaccinated cats were diluted to 1:50 in Buffer 3 (0.15 M sodium chloride, 0.001 M editic acid, 0.05 M TRIS base, 0.05% Tween 20, and 0.1% bovine serum albumin) and incubated with virus blot strips in separate wells of immunoblot plate for 18 hrs at 37° C. The blot strips were washed individually with wash solution (0.15 M NaCl and 0.05% Tween 20 in deionized H2O), incubated with biotinylated anti-cat IgG (Vector Laboratories, Burlingame, Calif.) for 1 hr at 37° C., and washed three times with wash solution. The strips were then incubated individually with horseradish peroxidase conjugated Streptavidin (Vector Laboratories) for 30 min. After extensive washing, each strip was incubated with a fresh substrate solution (0.05% diaminobenzidine, 400 μg/ml NiCl2, and 0.01% H2O2 in 0.1 M Tris buffer, pH 7.4) at room temperature. The reaction was stopped with excess distilled H2O upon establishment of visible bands, and the strips were blot dried. The molecular weights of the bands on the immunoblots were then determined by comparing them with the migration distance of the molecular weights standards on a strip previously stained with amido black. Positive and negative control serum were included in each immunoblot analysis as internal controls for diagnostic evaluation.
- The viral antigen-specific ELISA has been previously described (Yamamoto et al., 1991a; Yamamoto et al., 1993). Sucrose gradient purified FIVPet and surface envelope (SU) and transmembrane (TM) peptides of both conserved (C) and variable (V) regions of FIVPet were coated on 96 well Immunolon plates (Dynatech Laboratories, Inc., Chantilly, Va.) at 250 ng/well with bicarbonate buffer (pH 9.6) for 12 to 18 hours at 37° C. and were used as substrates for ELISA. The amino acid sequence of the SU-V3-2 peptide is: Gly Ser Trp Phe Arg Ala Ile Ser Ser Trp Lys Gln Arg Asn Arg Trp Glu Trp Arg Pro Asp Phe (SEQ ID NO. 1); and the amino acid sequence of the TM-C1 peptide is: Gln Glu Leu Gly Cys Asn Gln Asn Gln Phe Phe Cys Lys Ile (SEQ ID NO: 2). The synthetic peptides were synthesized on a Biosearch 9500 peptide synthesizer (Biosearch, San Rafael, Calif.) using FMOC peptide synthesis chemistry (Magazine et al., 1988). Purity of the synthesized peptides was determined by the presence of a single peak on a reversed-phase high-performance liquid chromatography and confirmed by amino acid sequence analysis performed on the peak sample.
- The peptide coated plates were washed once with
Buffer 3 immediately prior to use. The serum samples were diluted at 1:200 inBuffer 3 and incubated in the FIV antigen coated wells for 1 hr at 37° C., then washed 6 times. The wells were washed with wash solution, incubated with biotinylated anti-cat IgG (Vector Laboratories, Burlingame, Calif.) for 1 hr at 37° C., washed 6-times, and incubated with horseradish peroxidase conjugated Streptavidin (Vector Laboratories) for 1 hr at 37° C. The wells were then washed 6 times with wash solution and incubated with ELISA substrate solution (0.005% tetramethylbenzidine and 0.015% H2O2 in 0.96-% citrate solution) at room temperature. The reaction was stopped with 0.1 M hydrofluoric acid upon establishment of visible reaction color in the sequentially diluted standards consisting of known FIV-positive cat serum. Light absorption was measured with a BioRad ELISA reader (Bio-Rad Laboratories, Hercules, Calif.) at optical density of 414 nm. - Polymerase Chain Reaction (PCR). The proviral DNA levels of infected cells were monitored by differential PCR, which was recently developed to distinguish multiple FIV strains from the same or different subtypes (Okada et al., 1994). As a means of increasing the sensitivity of PCR, the nested PCR primer sets shown in Table 1 were used. PCR was performed in a two stage reaction, first with a pair of outer primers (common for all FIV strains) under conditions as described in Okada et al., 1994. In the second PCR stage, 1/25 of the first stage product was amplified using the inner primers (specific for each FIV strain). Using nested PCR, cells infected with FIVPet, FIVUK8, FIVBang, FIVAom1, FIVAom2 and FIVShi can be distinguished from each other.
-
TABLE 1 Primer sets for differential PCR. Subtype Strain Primer (orientation) Sequence Position* Outer Primer Sets All NA common (+) GAAATGTATAATATTGCTGG (SEQ ID NO: 3) 1570-1589 common (−) GAATTGATTTTGATTACATCC (SEQ ID NO: 4) 2112-2092 Inner Primer Sets A Petaluma Pet (+) TAGTAGTTATAGTGGTACTA (SEQ ID NO: 5) 1659-1678 Pet (−) TCTTTAAGGCTTCAGTCACCT (SEQ ID NO: 6) 1984-1964 UK-8 UK8 (+) GTACAAATAGTAGTAGTACAA (SEQ ID NO: 7) 1646-1666 UK8 (−) TCTTTAAGGCTTCAGTCACCT (SEQ ID NO: 8) 1984-1964 B Bangston Bang (+) GGGACTACTAGCAATGGAATA (SEQ ID NO: 9) 1654-1674 Bang (−) AGTGCCTCAGTTATTTTATCC (SEQ ID NO: 10) 1979-1959 Aomori-1 Aol (+) TGGGACTGATGATAGTAAAAC (SEQ ID NO: 11) 1654-1674 Aol (−) AGTGCCTCAGTTATTTTATCC (SEQ ID NO: 12) 1979-1959 Aomori-2 Ao2 (+) TGGGACTGATAATAGTGAAAC (SEQ ID NO: 13) 1654-1674 Ao2 (−) AGTGCCTCAGTTATTTTATCC (SEQ ID NO: 14) 1979-1959 D Shizuoka Shi (+) TCATCATTTCCAACATGTC (SEQ ID NO: 15) 1663-1681 Shi (−) AATGCTTCAGTTATTTGATC (SEQ ID NO: 16) 1979-1960 *Nucleotide positions correspond to those of Petaluma sequence and the numbers represent the position from the start of env sequence. - The approximate amount of proviral DNA per cell was determined by semi-quantitative PCR, in which varying dilutions of DNA extracted from a known number of cells are made. For example, if 105 cells are used for DNA extraction, then a 10−5 dilution of the DNA preparation will approximately correspond to the DNA present in a single cell. PCR was performed on these varying DNA dilutions and the final dilution that gave a positive PCR result is considered the end-point dilution. The number of cells corresponding to the end-point dilution is used to determine the percentage of cells infected with virus in a given cell preparation according to the following formula:
-
- where Z=the number of cells corresponding to the end-point dilution.
- Reverse transcriptase (RT) assay. The presence of RNA-dependent DNA polymerase (RT) was assayed in cell culture supernatants essentially as described by Rey et al. The RT assay for detecting FIV used poly(rA)-oligo(dT12-18) as an exogenous template primer, four different deoxyribonucleotide triphosphates, 20 mM KCl with Mg++ as divalent cation and 5 μCi [3H]-labeled thymidine triphosphate (TTP) per sample. Five μCi [3H]TTP gave an average total count of 1,200,000 cpm using scintillation fluid mixture (1 part xylene to 9 part Research Products International biodegradable counting scintillant) on a Beckman LS250 scintillation counter (Beckman Instruments, Inc., Palo Alto, Calif.). As a result, RT values for samples tested will be below 1,200,000 cpm/ml.
- Viral neutralization assay. A strategy for developing strain- and subtype-specific VN assays has been described (Okada et al., 1994). Serial dilutions of heat-inactivated sera were incubated with 100 TCID50 of each FIV strain for 45 minutes at 37° C. in a 24-well plate prior to addition of feline peripheral blood mononuclear cells (PBMC) (4×105 cells/ml) or FIV-susceptible FeT-1C cells (2×105 cells/ml). After 3 days of culturing, the cells were washed once with Hank's balanced salt solution to remove residual virus from the culture and then the cells were resuspended in fresh culture media (RPMI-1640 containing 10% heat-inactivated fetal calf serum, 10 mM HEPES buffer, 50 μg/ml gentamicin, 5×10−5 M 2-mercaptoethanol, and 100 Units/ml human recombinant IL-2). Virus infection of cells was monitored by Mg++-dependent RT assays of the culture fluids harvested on 9, 12, 15, and 18 days of culture. Sera were considered positive for VN antibodies when RT activity was ≦25% of infected control cultures consisting of SPF serum.
- Following are examples which illustrate procedures, including the best mode, for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.
- A novel interleukin-2 (IL-2) dependent feline T-cell line, designated as FeT-1C, which is a mother line of an IL-2-dependent FeT-1M clone, was used to establish individual cell lines chronically infected with either FIVPet, FIVDix, FIVUK8, FIVBang, FIVAom2, or FIVShi. The FeT-1M clone (also referred to as FIV-Fet1M) has been described in U.S. Pat. No. 5,275,813, which is herein incorporated by reference, and was used to produce an IL-2-independent cell line, FL-4 (also described in U.S. Pat. No. 5,275,813), that chronically produces FIVPet. The FeT-1C cell line is highly infectable with different isolates from FIV subtypes A, B, and D. Long-term passaging of the FeT-1C cell line decreases its infectability, especially to FIV subtype D; therefore, the passage number should be less than about 35 passages for optimal FIV infection rates or for its use in VN assays. Semi-quantitative PCR and viral core antigen analyses indicated that all the cell lines exposed to FIV were significantly infected with individual FIV strains.
- An IL-2 independent feline cell line susceptible to FIV infection has also been developed from FeT-1C cells. This cell line, designated as FeT-J, can be infected with FIV by co-culture using FIV infected media or cells. For example, an FIVBang-infected FeT-1C cell line was co-cultured in the absence of IL-2 with uninfected FeT-J cells to establish an IL-2-independent FIVBang-infected FeT-J cell line (designated as Bang/FeT-J). In the co-culture method of infection, Bang/FeT-1C cells were combined with uninfected FeT-J cells at a ratio of from about 2:1 to about 10:1 (infected:uninfected). The cell mix was cultured in media in the absence of IL-2 for several days and the FeT-1C cells were allowed to die off. The remaining cells consisted of FIVBang-infected FeT-J cells. Thus, FIV-infected FeT-1C cells can be used to infect FeT-J cells and establish IL-2-independent FeT-J cell lines infected with different FIV subtypes. The co-cultivation method with FIV infected FeT-1C cells resulted in IL-2-independent FeT-J cell lines producing moderate to high levels of different FIV subtypes.
- The FeT-1C cell line was also infected with FIVShi and extensively passaged to produce an IL-2-dependent cell line designated as Shi/FeT-1C. The Shi/FeT-1C cell line was later co-cultured with FeT-J in the absence of IL-2 and the resulting IL-2-independent FIVShi-infected cell line was designated as Shi/FeT-J. The IL-2-independent Shi/FeT-J cell line produces higher levels of FIVShi than IL-2-dependent Shi/FeT-1C cell line (
FIG. 1 ). - The development of a FeT-J cell line infected with FIVBang was also performed without the use of the FeT-1C cell line. The FeT-J cell line was directly infected with cell-free FIVBang inoculum and extensively passaged without IL-2. The resulting IL-2-independent FIVBang producer cell line was designated Bang/FeT-J. The Bang/FeT-J cell line produced higher levels of FIVBang than the IL-2-dependent Bang/FeT-1C cell line which was developed by infecting FeT-1C cell line with FIVBang (
FIG. 1 ). - FIV-infected cells were removed from supernatants by centrifugation, inactivated, and used as vaccine. Similarly, whole FIV virus were pelleted from infected cell-free supernatant by ultracentrifugation and inactivated. Both infected cells and virus were inactivated by treatment with 1.25% paraformaldehyde for 24 hours at 5° C., followed by extensive washing or dialysis against PBS, respectively. This method efficiently inactivates FIV without loss of immunogenicity. FIV immunogens produced according to the subject method are highly effective for inducing protective immunity (Yamamoto et al., 1993; Yamamoto et al., 1991a; Yamamoto et al., 1991b). It is contemplated that attenuated viral isolates could also be used in the vaccine compositions of the subject invention.
- Although an FIVShi-infected FeT-1C cell line was superinfected with the FIVPet strain to produce a single cell line infected with multiple subtypes of FIV (i.e., a multi-subtype A/D FeT-1C cell line), within two months of co-infection the FIVShi proviral levels decreased from 50% to less than 5% whereas FIVPet proviral levels concomitantly increased to about 50%. Thus, the maintenance of a single cell line infected with multiple subtypes of FIV for use as an FIV vaccine is not the preferred embodiment of the subject invention.
- Consequently, in one embodiment of the subject invention, vaccine compositions were developed from two individual cell lines, each line being infected with a different FIV subtype. In a specific embodiment, the dual-subtype FIV vaccine composition comprised a combination of an FIV subtype A-infected cell line (Pet/FL-4) with an FIV subtype D-infected cell line (Shi/FeT-1C). The A-subtype and D-subtype infected cell lines were inactivated as described, combined in equal cell numbers (2.5×107 cells each in 250 μg of MDP) and used to immunize cats. Three SPF cats were vaccinated with inactivated Pet/FL-4 cells and four other cats were vaccinated with inactivated Shi/FeT-1C cells (2.5×107 cells/dose). After a series of four vaccinations, the dual-subtype (Pet/FL-4 and Shi/FeT-1C) vaccine induced anti-FIV antibodies, including significant VN antibody titers, to both FIV strains tested (
FIG. 2 and Table 2, Trial I). Four dual-subtype (Pet/FL-4 and Shi/FeT-1C) vaccinated cats were challenged with FIVBang (50 CID50). All three Pet/FL-4 vaccinated and two of the Shi/FeT-1C vaccinated cats were challenged with 50 CID50 of FIVBang. The two remaining Shi/FeT-1C vaccinated cats were challenged with 50 CID50 of FIVShi. - All dual-subtype vaccinated cats were negative for FIVBang by virus isolation and PCR of PBMC at 6 weeks post-infection (pi), whereas all sham immunized cats were positive for either FIVBang or FIVShi by virus isolation and PCR at 6 weeks post-infection (Table 2, trial I). In contrast, one cat each from Pet/FL-4 vaccinated and Shi/FeT-1C vaccinated groups which was challenged with FIVBang was positive for FIVBang. As expected, all cats vaccinated with FIVShi and subsequently challenged with FIVShi were negative for FIVShi at 6 weeks post-infection. Thus, the dual-subtype vaccine specifically exemplified prevented or delayed infection against homologous FIVShi challenge as well as against heterologous FIVBang challenge.
- The dual-subtype vaccinated cats (Pet/FL-4 cells and Shi/FeT-1C cells) developed FIV antibodies specific for the viral core protein p25 (also call FIV p28) after the second immunization (
FIG. 2 ). Higher antibody titers to other viral antigens were demonstrated after the third to fourth immunization. VN antibodies to FIVPet developed after the second immunization, whereas VN antibodies to FIVShi developed after the fourth immunization (Table 4). CTL responses to FIVPet and FIVShi were detected as early as the third immunization in all cats tested (Table 3) and stronger CTL responses to both strains were developed after the fourth immunization. Further, two of the three cats tested developed CTL responses to FIVBang after the fourth immunization. Results indicate that after 4 vaccinations, the dual-subtype vaccine induced strong CTL responses to FIVPet and FIVShi (Table 3) and high FIV antibodies, including VN antibody titers, to both FIV strains (Table 4). - The cats immunized with inactivated Shi/FeT-1C cells developed FIV antibodies specific for the viral core protein p25 after the second immunization and antibodies to other viral antigens after the third immunization (
FIG. 2 ). VN antibodies to FIVShi in these cats developed after the fourth immunization, whereas VN antibodies to FIVPet were not detected over the course of the immunizations. Both of the Shi/FeT-1C vaccinated cats developed CTL responses to FIVShi only after the fourth immunization but did not develop CTL responses to FIVPet, even after the fourth immunization (Table 3). - Cats immunized with inactivated Pet/FL-4 cells developed antibodies to p25 after the second immunization (
FIG. 2 ) and to other viral antigens, including VN antibodies to FIVPet, after the second to third immunization (Table 4). The only CTL responses detected in cats immunized with Pet/FL-4 cells were to FIVPet. Overall, the dual subtype FIV vaccine induced more rapid and higher VN antibody titers and CTL responses to both FIV strains than the single-subtype vaccine. Sham immunized SPF cats did not develop viral antibodies, VN antibodies, or anti-FIV CTL responses. -
TABLE 2 Protection of cats with multi-subtype FIV vaccine Average VN Antibodies at No. FIV Day 0 pi against2 Virus Vaccine type of Cats challenge strain (CID50)1 Pet Shi Bang Isolation & PCR Protection Rate (%) Dual-subtype Vaccine Trial I (A + D): Pet/FL-4 cell + Shi/FeT-1C cell 5 FIVBang (50 CID50) 1000 550 <10 3/5 Negative 3/5 (60% at 6 wk pi) Pet/FL-4 cell 3 FIVBang (50 CID50) 1000 <10 <10 All Positive 0/3 (0% at 6 wk pi) Shi/FeT-1C cell 2 FIVBang (50 CID50) <10 75 <10 All Positive 0/2 (0% at 6 wk pi) Shi/FeT-1C cell 2 FIVShi (50 CID50) <10 30 <10 All Positive 0/2 (0% at 6 wk pi) sham 3 FIVBang (50 CID50) <10 <10 <10 All Positive 0/3 (0% at 6 wk pi) sham 2 FIVShi (50 CID50) <10 <10 <10 All Positive 0/2 (0% at 6 wk pi) Triple-subtype Vaccine Trial II (A + B + D):4 Pet/FL-4 cell + Bang/FeT-J cell + 3 FIVUK8 1000 370 1000 NA 2/3 (67% at 24 wk pi) Shi/FeT-1C cell5 Bang/FeT-J cell 2 FIVUK8 <10 <10 1000 NA 0/2 Bang/FeT-J cell 2 FIVBang <10 <10 100 NA 1/2 Sham Uninfected FeT-J 2 FIVUK8 <10 <10 <10 NA Uninfected FeT-J 2 FIVUK8 <10 <10 <10 NA 0/2 Sham Adjuvant only 1 FIVUK8 <10 <10 <10 NA 0/2 Uninfected FeT-J 1 FIVBang <10 <10 <10 NA 0/1 Sham Adjuvant only 2 FIVBang <10 <10 <10 NA 1/2 1All FIV challenge inocula were produced in vitro by infecting primary PBMC from SPF cats. All aliquoted inocula were stored in −70° C. and thawed at room temperature just prior to use. 2pi = post FIV infection. 3ND = not done. 4VN results are after third vaccination. 5Fourth vaccination will be performed with inactivated Shi/FeT-J cells instead of inactivated Shi/FeT-1C cells. -
TABLE 3 CTL responses from dual-subtype vaccinated cats. CHROMIUM RELEASE (% LYSIS) 3rd Vaccination 4th Vaccination Effector:Target Effector:Target Vaccine CTL Ratio Ratio Cat# Type Target 10:1 50:1 100:1 10:1 50:1 100:1 K55 Pet + Shi Pet 0 9 20 17 25 33 Bang ND ND ND 0 0 14 Shi 0 9 8 7 11 17 3L4 Pet + Shi Pet 0 11 19 0 11 19 Bang ND ND ND 0 0 0 Shi 0 9 13 0 9 17 N55 Pet + Shi Pet ND ND ND 0 11 17 Bang ND ND ND 0 0 7 Shi ND ND ND 0 9 15 M55 Shi Pet 0 0 0 0 0 0 Bang ND ND ND 0 0 0 Shi 0 0 0 0 7 15 007 Shi Pet 0 0 0 0 0 0 Bang ND ND ND 0 0 0 Shi 0 0 0 0 0 8 2H5D Pet Pet 0 7 15 6 15 25 Bang ND ND ND 0 0 0 Shi 0 0 0 0 0 0 3G1 Pet Pet 0 10 14 6 13 19 Bang ND ND ND 0 0 0 Shi 0 0 0 0 0 0 H7P Sham Pet 0 0 0 0 0 0 Bang ND ND ND 0 0 0 Shi 0 0 0 0 0 0 -
TABLE 4 Virus neutralization (VN) titers from dual-subtype vaccinated cats. Post 2nd Post 4th Cat Pre-Vaccination Vaccination Vaccination No. FIV Vaccine Pet Bang Shi Pet Bang Shi Pet Bang Shi K55 Pet + Shi >10 >10 >10 100 <10 <10 1000 <10 100 3L4 Pet + Shi >10 >10 >10 100 <10 <10 1000 <10 1000 N55 Pet + Shi >10 >10 >10 10 <10 <10 1000 <10 1000 973 Pet + Shi >10 >10 >10 10 <10 <10 1000 <10 100 M55 Shi >10 >10 >10 >10 >10 <10 <10 <10 50 006 Shi >10 >10 >10 >10 >10 <10 <10 <10 100 007 Shi >10 >10 >10 >10 >10 <10 <10 <10 10 999 Shi >10 >10 >10 >10 >10 <10 <10 <10 50 3G1 Pet >10 >10 >10 <10 <10 <10 1000 <10 <10 3G2 Pet >10 >10 >10 10 <10 <10 1000 <10 <10 2H5D Pet >10 >10 >10 100 <10 <10 1000 <10 <10 8C2 Sham >10 >10 >10 >10 >10 >10 >10 >10 >10 8C8 Sham >10 >10 >10 >10 >10 >10 >10 >10 >10 H7P Sham >10 >10 >10 >10 >10 >10 >10 >10 >10 8G8 Sham <10 <10 <10 <10 <10 <10 <10 <10 <10 RF5 Sham <10 <10 <10 <10 <10 <10 <10 <10 <10 - In a preferred embodiment, the vaccine composition of the subject invention comprises a triple-subtype FIV vaccine prepared from three cell lines, each cell line having been infected with a viral strain from a different FIV subtype (A or B or D). Three specific pathogen free cats were immunized with a triple-subtype (FIVPet+FIVBang+FIVShi) vaccine. Other cats were immunized with single-subtype FIV Bang vaccines to evaluate the immunogenicity of macrophage-tropic FIVBang as a component of the vaccine. The VN antibody titer results indicate that both triple-subtype (FIVPet+FIVBang+FIVShi) and single-subtype FIVBang vaccines elicited high antiviral antibody titers even after the second immunization (Table 2, trial II and Table 5). Thus, both lymphotropic and macrophage-tropic FIV can be used as components of the vaccine compositions of the present invention.
- The three SPF cats immunized with a combination of inactivated Pet/FL-4, inactivated Bang/FeT-J, and inactivated Shi/FeT-1C cells (2.5×107 cells each in 250 μg total of MDP) developed FIV antibodies specific for the viral core protein p25 and to other viral antigens, including FIV SU and TM envelope protein, after the second immunization (
FIGS. 3 , 4, 5). VN antibodies to FIVPet, FIVBang and FIVShi developed in the majority of cats soon after the second immunization and in all cats by the third immunization (Table 5). In addition, one cat had VN antibodies that cross reacted to FIVUK8 after third immunization. Four SPF cats immunized only with inactivated Bang/FeT-J cells developed FIV antibodies specific for the viral core protein p25 and other viral antigens after the second immunization (FIG. 3 ). VN antibodies to FIVBang in these cats developed after the second immunization (Table 5), whereas VN antibodies to FIVPet and FIVUK8 were not detected over the course of the immunizations. CTL responses of cats immunized three times with the triple-subtype FIV vaccine (Pet/FL-4, Bang/FeT-J and Shi/FeT-1C cells) to FIV A, B and D subtype target cells are shown in Table 6. CTL responses to all three FIV subtypes tested were detected. Thus, the triple-subtype vaccine induced a broad CTL response and more rapid and higher VN and SU-envelope antibody titers than the single-subtype vaccine. Neither uninfected FeT-J nor Sham immunized SPF cats developed viral antibodies or VN antibodies. -
TABLE 5 Virus neutralization (VN) titers from triple-subtype vaccinated cats. Pre-Vaccination Post 2nd Vaccination Post 3rd Vaccination CAT# FIV VACCINE Pet Bang Shi UK8 Pet Bang Shi UK8 Pet Bang Shi UK8 J55 Pet + Bang + Shi <10 <10 <10 <10 1000 1000 <10 <10 1000 1000 10 <10 QY1 Pet + Bang + Shi <10 <10 <10 <10 100 1000 100 <10 1000 1000 1000 <10 TAS Pet + Bang + Shi <10 <10 <10 <10 <10 1000 10 <10 100 1000 100 100 BEA Bang <10 <10 <10 <10 <10 100 <10 <10 <10 1000 <10 <10 QU8 Bang <10 <10 <10 <10 <10 10 <10 <10 <10 100 <10 <10 RD2 Bang <10 <10 <10 <10 <10 100 <10 <10 <10 100 <10 <10 3G4 Uninfected FeT-J <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 3G5 Uninfected FeT-J <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 3G6 Sham <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 3G7 Sham <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 The VN titers are the average titers of two separate VN assays. -
TABLE 6 CTL responses of triple-subtype vaccinated cats after 3rd immunization CTL Activity (% chromium Cat No. Target FIV E:T Ratio release) QY1 FIV Pet 100 44% 50 21% 10 4 % QY1 FIV Bang 100 13% 50 6% 10 1 % QY1 FIV UK8 100 23% 50 8% 10 2 % Tas FIV Bang 100 8% 50 3% 10 1 % Tas FIV Shi 100 3% 50 1% 10 0.3 % J55 FIV UK8 100 10% 50 2% 10 1% - An assay for VN antibodies to FIV was also developed using the FeT-1C cells of the subject invention. Serum from FIVPet-infected cats and SPF cats vaccinated with inactivated Pet/FL-4 cells or inactivated FIVPet virus were tested for VN antibody titer using either FeT-1C cells or PBMC according to the VN assay method described herein. Sera from two SPF cats which were unvaccinated and FIV uninfected were used as control sera. Sera from vaccinated and FIV infected cats had a high VN antibody titer of 1000 or greater, whereas sera from unvaccinated SPF cats had no detectable VN antibody titer. The FeT-1C-based VN assay gives VN antibody titer results comparable to those obtained using primary PBMC from cats (Table 6). This finding demonstrates that VN antibody titers in a VN assay using FeT-1C cells correlates with those results obtained with a VN assay using PBMC. Therefore, FeT-1C cells can be advantageously used in place of PBMC in the standard VN assay for FIV since FeT-1C cells can be infected with all the FIV subtypes and can be readily propagated in tissue culture.
-
TABLE 7 VN titers assayed on FeT-1C and PBMC VN titers Serum source FeT-1C PBMC Vaccinated1 5000 5000 Vaccinated1 >1000 >1000 Infected2 1000 1000 Infected2 >1000 >1000 Uninfected cell <10 <10 immunized3 Uninfected cell <10 <10 immunized3 1Sera from inactivated Pet/FL-4 cell vaccinated cats 2Sera from FIVpet infected cats 3Sera from inactivated uninfected FeT-J immunized cats - In vitro studies were performed using FeT-1C cells to assess if FIV subtype reflected FIV immunotype. Immunotyping is important for understanding the role of VN antibodies in vaccine protection. Antisera from cats infected with FIV subtype A strains (FIVPet, FIVDix, FIVUK8), subtype B (FIVBang, FIVAom1), and subtype D (FIVShi) were tested for the ability to neutralize these strains in vitro using FeT-1C cells in the VN assay (
FIG. 6 ). All of the test antisera had neutralizing activity against the corresponding homologous FIV strain. FIVPet, a subtype A strain, was significantly cross-neutralized by antisera from cats infected with FIVDix. FIVPet differs from FIVDix by approximately 9% at surface envelope glycoprotein (Env) regions. Anti-sera from cats infected with FIV subtype A strains cross-neutralized subtype B FIVBang but did not neutralize subtype D FIVShi. Antisera from cats infected with subtype B and D strains only cross-neutralized other FIV strains within the homologous subtype. Further, antisera from cats infected with FIVUK8 neutralized FIVBang but did not neutralize FIV strains within subtype A. Although FIVUK8 is classified as subtype A (Sodora et al., 1994; Rigby et al., 1993; Kakinuma et al., 1995), these results suggest that antisera to FIVUK8 recognizes subtype B strains, but does not recognize subtype A strains, and may explain why inactivated FIVPet vaccines were ineffective against FIVUK8 and FIVShi (Johnson et al., 1994). Thus, a loose correlation exists between genotype and immunotype. Although genotypic analyses allow for FIV strain classification, cross-neutralization antibody studies reflect the immunogenicity of FIV strains, which is an important parameter in broad-range humoral protection elicited by vaccines. - The cell tropism of the FIV strains obtained from infected FeT-1C and infected FeT-J cell lines were compared to those FIV strains obtained from primary PBMC (Table 8). Two FIV isolates, FIVUK8 and FIVBang, are both equally lymphotropic and macrophage-tropic, whereas FIVShi is highly lymphotropic. FIVPet was more lymphotropic than macrophage-tropic and its cell tropism was not significantly affected by its cell source. The macrophage-tropism of FIVBang was not affected by the cell source of the virus. Since the cell tropism of the FIV strains from infected FeT-1C cell line is comparable to those produced from primary PBMC the virus grown in FeT-1C cells can be used as inoculum for VN assays and also as an in vivo inoculum for studies to evaluate therapeutic and prophylactic approaches.
-
TABLE 8 Cell tropism of FIV Isolates. TCID50 a FeT- Alveolar Primary FIV (Subtype) FIV Source 1C PBMC Macrophage Microglia Petaluma (A) PBMC 104 104 102 ND Petaluma (A) FeT-1Cb 104 104 101 ND Petaluma (A) FL-44 104 104 101 ND Dixon (A) FeT-1C 104 103 101 ND UK8 (A) PBMC 102 103 103 ND UK8 (A) FeT-1C 103 103 103 ND Bangston (B) PBMC 103 103 103 102 Bangston (B) FeT-1Cb 103 103 103 102 Bangston (B) FeT-Jb 103 103 103 102 Shizuoka (D) PBMC 102 103 <1 ND Shizuoka (D) FeT-1Cb 103 103 <1 ND Shizuoka (D) FeT-Jb 103 103 ND ND a All virus inocula were adjusted to 120,000 cpm/ml of RT activity before titration on 5 × 105 cells/ml of feline T cells (FeT-1C) or primary feline cells and the results represents the highest titer of the virus harvested over 21 days of culturing.bSame cells as the infected-cell vaccines. - It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.
-
- Pedersen, Niels C., Janet K. Yamamoto, U.S. Pat. No. 5,037,753, issued Aug. 6, 1991.
- Pedersen, Niels C., Janet K. Yamamoto, U.S. Pat. No. 5,118,602, issued Jun. 2, 1992.
- Byars, N. E., A. C. Allison (1987) “Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity,” Vaccine 5:223-228.
- Pedersen, N. C., E. W. Ho, M. L. Brown, J. K. Yamamoto (1987) “Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome,” Science 235:790-793.
- Yamamoto, J. K., N. C. Pedersen, E. W. Ho, T. Okuda, G. H. Theilen (1988a) “Feline immunodeficiency syndrome—a comparison between feline T-lymphotropic lentivirus and feline leukemia virus,” Leukemia, December Supplement 2:204S-215S.
- Yamamoto, J. K., E. Sparger, E. W. Ho, P. H. Andersen, T. P. O'Connor, C. P. Mandell, L. Lowenstine, N. C. Pedersen (1988) “Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats,” Am. J .Vet. Res. 49:1246-1258.
- Ackley, C. D., J. K. Yamamoto, N. B. Levy, N. C. Pedersen, M. D. Cooper (1990) “Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus,” J. Virol. 64:5652-5655.
- Olmsted, R. A., A. K. Barnes, J. K. Yamamoto, V. M. Hirsch, R. H. Purcell, P. R. Johnson (1989) “Molecular cloning of feline immunodeficiency virus,” Proc. Nat. Acad. Sci. 86:2448-2452.
- Olmsted, R. A., V. M. Hirsch, R. H. Purcell, P. R. Johnson (1989) “Nucleotide sequence analysis of feline immunodeficiency virus: Genome organization and relationship to other lentivirus,” Proc. Natl. Acad. Sci. USA 86:8088-8092.
- Talbott, R. L., E. E. Sparger, K. M. Lovelace, W. M. Fitch, N. C. Pedersen, P. A. Luciw, J. H. Elder (1989) “Nucleotide sequence and genomic organization of feline immunodeficiency virus,” Proc. Natl. Acad Sci. USA 86:5743-5747.
- Hosie, M. J., O. Jarrett (1990) “Serological responses of cats to feline immunodeficiency virus,” AIDS 4:215-220.
- Sodora, D. L., E. G. Shpaer, B. E. Kitchell, S. W. Dow, E. A. Hoover, J. I. Mullins (1994) “Identification of three feline immunodeficiency virus (FIV) env gene subtype and comparison of the FIV and human
immunodeficiency virus type 1 evolutionary patterns,” J. Virol. 68:2230-2238. - Rigby, M. A., E. C. Holmes, M. Pistello, A. Mackay, A. J. Leigh-Brown, J. C. Neil (1993) “Evolution of structural proteins of feline immunodeficiency virus: molecular epidemiology and evidence of selection for change,” J. Gen. Virol. 74:425-436.
- Kakinuma, S., K. Motokawa, T. Hohdatsu, J. K. Yamamoto, H. Koyama, H. Hashimoto (1995) “Nucleotide Sequence of Feline Immunodeficiency Virus: Classification of Japanese Isolates into Two Subtypes Which Are Distinct from Non-Japanese Subtypes,” Journal of Virology 69(6):3639-3646.
- Johnson, C. M., B. A. Torres, H. Koyama, J. K. Yamamoto (1994) “FIV as a model for AIDS vaccination,” AIDS Res. Hum. Retroviruses 10:225-228.
- Yamamoto, J. K., T. Hohdatsu, R. A. Olmsted, R. Pu, H. Louie, H. Zochlinski, V. Acevedo, H. M. Johnson, G. A. Soulds, M. B. Gardner (1993) “Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus,” J. Virol. 67:601-605.
- Yamamoto, J. K., T. Okuda, C. D. Ackley, H. Louie, H. Zochlinski, E. Pembroke, M. B. Gardner (1991a) “Experimental vaccine protection against feline immunodeficiency virus,” AIDS Res. Hum. Retroviruses 7:911-922.
- Yamamoto, J. K., C. D. Ackley, H. Zochlinski, H. Louie, E. Pembroke, M. Torten, H. Hansen, R. Munn, T. Okuda (1991b) “Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines,” Intervirol. 32:361-375.
- Murphy, F., D. W. Kingsbury (1990) “Virus Taxonomy,” In Fields Virology, 2nd Ed., B. N. Fields, D. M. Knipe et al., eds, Raven Press, New York,
Chapter 2, pp. 9-36. - Louwagie, J., F. E. McCutchan, M. Peeters, T. P. Brennan, E. Sanders-Buell, G. A. Eddy, G. van den Grosen, K. Fransen, G. M. Gershy-Damet, R. Deleys, D. S. Burke (1993) “Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes,” AIDS 7:769-780.
- Rey, M. A., B. Spire, D. Dormont, F. Barre-Suinoussi, L. Montagnier, J. C. Chermann (1984) “Characterization of the RNA dependent DNA polymerase of a new human T-lymphotropic retrovirus 1 (lymphadenopathy associated virus),” Biochem. Biophys. Res. Commun. 21:1247-1253.
- Magazine, H. I, J. M. Carter, J. K, Russell, B. A. Torres, B. M. Dunn, H. M. Johnson (1988) “Use of synthetic peptides to identify and end terminal epitope on mouse gama ifn that may be involved in function,” Proc. Natl. Acad. Sci. USA 85:1237.
- Okada, S., R. Pu, E. Young, W. Stoffs, J. K. Yamamoto (1994) “Superinfection of cats with FIV Subtypes A and B,” AIDS Res. Hum. Retroviruses 10:1739-1746.
- Yamamoto, Janet K., Niels C. Pedersen, U.S. Pat. No. 5,275,813, issued Jan. 4, 1994.
- Merrifield, R. B. (1963) J. Amer. Chem. Soc. 85:2149-2156.
Claims (4)
1. A vaccine composition that induces a protective immune response against two or more subtypes of FIV in an animal susceptible to infection by FIV, comprising an effective amount of an FIV immunogen to induce said immune response, wherein said FIV immunogen comprises an immunogen or immunogens from or comprising at least two different FIV subtypes, and wherein said immunogen or immunogens comprises at least one recombinant viral vector FIV construct.
2. A vaccine composition that induces a protective immune response against two or more subtypes of FIV in an animal susceptible to infection by FIV, comprising an effective amount of an FIV immunogen to induce said immune response, wherein said FIV immunogen comprises an immunogen or immunogens from or comprising at least two different FIV subtypes, and wherein said immunogen or immunogens comprise cell-free whole or partial FIV virus or a cell or cells infected with FIV virus, wherein said FIV virus or cell is treated by exposure to paraformaldehyde, formalin, phenol, UV light, or heat to attenuate or inactivate said FIV virus or said FIV virus infecting said cell prior to administration of said vaccine to said animal.
3. A method for inducing a protective immune response against two or more subtypes of FIV in an animal susceptible to infection by FIV, comprising administering to said animal an effective amount of a vaccine composition comprising an FIV immunogen, wherein said FIV immunogen comprises an immunogen or immunogens from or comprising at least two different FIV subtypes, and wherein said immunogen or immunogens comprises at least one recombinant viral vector FIV construct.
4. A method for inducing a protective immune response against two or more subtypes of FIV in an animal susceptible to infection by FIV, comprising administering to said animal an effective amount of an FIV immunogen to induce said immune response, wherein said FIV immunogen comprises an immunogen or immunogens from or comprising at least two different FIV subtypes, and wherein said immunogen or immunogens comprise cell-free whole or partial FIV virus or a cell or cells infected with FIV virus, wherein said FIV virus or cell is treated by exposure to paraformaldehyde, formalin, phenol, UV light, or heat to attenuate or inactivate said FIV virus or said FIV virus infecting said cell prior to administration of said vaccine to said animal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/803,033 US20090263417A1 (en) | 1995-08-25 | 2007-05-11 | Multi-subtype FIV vaccines |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51938695A | 1995-08-25 | 1995-08-25 | |
PCT/US1996/013580 WO1997007817A1 (en) | 1995-08-25 | 1996-08-23 | Multi-subtype fiv vaccines |
US09/512,746 US6447993B1 (en) | 1995-08-25 | 1997-10-01 | Multi-subtype FIV vaccines |
US09/025,610 US6254872B1 (en) | 1995-08-25 | 1998-02-18 | Multi-subtype FIV vaccines |
US09/707,532 US6544528B1 (en) | 1995-08-25 | 2000-11-07 | Multi-subtype FIV vaccines |
US10/408,701 US7267824B2 (en) | 1995-08-25 | 2003-04-07 | Multi-subtype FIV vaccines |
US11/803,033 US20090263417A1 (en) | 1995-08-25 | 2007-05-11 | Multi-subtype FIV vaccines |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/408,701 Continuation US7267824B2 (en) | 1995-08-25 | 2003-04-07 | Multi-subtype FIV vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090263417A1 true US20090263417A1 (en) | 2009-10-22 |
Family
ID=46255908
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/025,610 Expired - Lifetime US6254872B1 (en) | 1995-08-25 | 1998-02-18 | Multi-subtype FIV vaccines |
US09/707,532 Expired - Lifetime US6544528B1 (en) | 1995-08-25 | 2000-11-07 | Multi-subtype FIV vaccines |
US10/408,701 Expired - Fee Related US7267824B2 (en) | 1995-08-25 | 2003-04-07 | Multi-subtype FIV vaccines |
US11/803,033 Abandoned US20090263417A1 (en) | 1995-08-25 | 2007-05-11 | Multi-subtype FIV vaccines |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/025,610 Expired - Lifetime US6254872B1 (en) | 1995-08-25 | 1998-02-18 | Multi-subtype FIV vaccines |
US09/707,532 Expired - Lifetime US6544528B1 (en) | 1995-08-25 | 2000-11-07 | Multi-subtype FIV vaccines |
US10/408,701 Expired - Fee Related US7267824B2 (en) | 1995-08-25 | 2003-04-07 | Multi-subtype FIV vaccines |
Country Status (1)
Country | Link |
---|---|
US (4) | US6254872B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021119459A3 (en) * | 2019-12-11 | 2021-10-07 | Illumina, Inc. | Immobilization in flow cells |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL186706B1 (en) * | 1995-08-25 | 2004-02-27 | Univ California | Vaccines against many sub-types of fiv |
US6254872B1 (en) * | 1995-08-25 | 2001-07-03 | University Of Florida | Multi-subtype FIV vaccines |
TW586934B (en) * | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
US9974847B2 (en) * | 2000-08-24 | 2018-05-22 | Immunitor USA, Inc. | Treatment and prevention of tuberculosis |
AU2002244103A1 (en) * | 2001-02-22 | 2002-09-12 | University Of Florida | Materials and methods for detecting, preventing, and treating hiv and fiv retroviral infection |
US7008650B2 (en) * | 2001-08-09 | 2006-03-07 | Lam Paul Y S | Compositions for the treatment of acquired immunodeficiency disease |
US20050103097A1 (en) * | 2002-01-24 | 2005-05-19 | Carsten Faltum | Sensor |
US7345152B2 (en) | 2002-09-12 | 2008-03-18 | Wyeth | Monoclonal antibody specific for an epitope of inactivated feline immunodeficiency-encoded glycoprotein |
US7658927B2 (en) * | 2003-05-12 | 2010-02-09 | University Of Florida Research Foundation, Inc. | Materials and methods for immunizing against FIV infection |
CA2525641A1 (en) * | 2003-05-12 | 2004-11-25 | University Of Florida Research Foundation, Inc. | Materials and methods for immunizing against fiv infection |
DE602004021829D1 (en) * | 2003-09-11 | 2009-08-13 | Idexx Lab Inc | METHOD FOR DETECTING THE FELINE IMMUNE WEAK VIRUS |
AU2005267607B8 (en) * | 2003-09-11 | 2009-07-16 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
EP1709447B1 (en) * | 2003-12-18 | 2009-06-24 | Idexx Laboratories, Inc. | Method for detecting feline immunodeficiency virus |
DE602005027326D1 (en) * | 2004-02-19 | 2011-05-19 | Idexx Lab Inc | METHOD AND DEVICE FOR DETECTING CAT IMMUNE WEAK VIRUS |
EP1761564A1 (en) * | 2004-06-30 | 2007-03-14 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
CA2576930C (en) * | 2004-06-30 | 2011-06-07 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein |
US7291338B2 (en) * | 2005-03-09 | 2007-11-06 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
AU2010308625A1 (en) * | 2009-10-21 | 2012-05-10 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Methods for diagnosis of immune responses against viruses |
WO2011123781A1 (en) | 2010-04-02 | 2011-10-06 | Idexx Laboratories, Inc. | Detection of feline immunodeficiency virus |
US10219986B2 (en) | 2015-03-04 | 2019-03-05 | Modern Ideas LLC | Stabilized calcium phosphate and methods of forming same |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5037753A (en) * | 1987-08-26 | 1991-08-06 | The Regents Of The University Of California | Feline t-lymphotropic lentivirus |
US5118602A (en) * | 1987-08-26 | 1992-06-02 | The Regents Of The University Of California | Feline T-lymphotropic lentivirus assay |
US5510108A (en) * | 1995-02-01 | 1996-04-23 | Olin Corporation | Sanitizer for swimming pools, spas, and hot tubs |
US5820869A (en) * | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US5833993A (en) * | 1994-04-29 | 1998-11-10 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
US5846825A (en) * | 1995-08-25 | 1998-12-08 | University Of Florida | Feline derived T-cell lines for producing FIV |
US6107077A (en) * | 1987-08-26 | 2000-08-22 | Yamamoto; Janet K. | Feline lymphoid cell lines capable of producing FIV for FIV diagnostics and vaccines |
US6254572B1 (en) * | 1996-11-22 | 2001-07-03 | Liebel Flarsheim Company | Medical fluid injector having watchdog circuit |
US6544528B1 (en) * | 1995-08-25 | 2003-04-08 | University Of Florida Research Foundation, Inc. | Multi-subtype FIV vaccines |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2299892A (en) | 1991-07-05 | 1993-02-11 | Regents Of The University Of California, The | Feline lymphoid cell lines capable of producing fiv |
WO1994020622A1 (en) | 1993-03-11 | 1994-09-15 | Akzo Nobel N.V. | Polypeptide fragment capable of inducing neutralising antibodies against feline immuno-deficiency virus |
IT1276509B1 (en) | 1995-03-31 | 1997-10-31 | Istituto Superiore Della Sanit | VACCINE FOR THE IMMUNE PROPHYLAXY OF FELINE IMMUNODEFICIENCY VIRUS INFECTION OF DOMESTIC CAT. |
-
1998
- 1998-02-18 US US09/025,610 patent/US6254872B1/en not_active Expired - Lifetime
-
2000
- 2000-11-07 US US09/707,532 patent/US6544528B1/en not_active Expired - Lifetime
-
2003
- 2003-04-07 US US10/408,701 patent/US7267824B2/en not_active Expired - Fee Related
-
2007
- 2007-05-11 US US11/803,033 patent/US20090263417A1/en not_active Abandoned
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6107077A (en) * | 1987-08-26 | 2000-08-22 | Yamamoto; Janet K. | Feline lymphoid cell lines capable of producing FIV for FIV diagnostics and vaccines |
US5118602A (en) * | 1987-08-26 | 1992-06-02 | The Regents Of The University Of California | Feline T-lymphotropic lentivirus assay |
US5275813A (en) * | 1987-08-26 | 1994-01-04 | The Regents Of The University Of California | Methods and compositions for vaccinating against feline immunodeficiency virus |
US5037753B1 (en) * | 1987-08-26 | 1994-03-15 | The Regents Of The University Of California | Feline t-lymphotropic lentivirus |
US5037753B2 (en) * | 1987-08-26 | 1998-06-16 | Univ California | Feline t-lymphotrophic lentivirus |
US5037753A (en) * | 1987-08-26 | 1991-08-06 | The Regents Of The University Of California | Feline t-lymphotropic lentivirus |
US5833993A (en) * | 1994-04-29 | 1998-11-10 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
US5510108A (en) * | 1995-02-01 | 1996-04-23 | Olin Corporation | Sanitizer for swimming pools, spas, and hot tubs |
US5820869A (en) * | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US5989562A (en) * | 1995-06-07 | 1999-11-23 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US5846825A (en) * | 1995-08-25 | 1998-12-08 | University Of Florida | Feline derived T-cell lines for producing FIV |
US6447993B1 (en) * | 1995-08-25 | 2002-09-10 | University Of Florida Research Foundation, Inc., | Multi-subtype FIV vaccines |
US6544528B1 (en) * | 1995-08-25 | 2003-04-08 | University Of Florida Research Foundation, Inc. | Multi-subtype FIV vaccines |
US6605282B2 (en) * | 1995-08-25 | 2003-08-12 | University Of Florida Research Foundation, Inc. | Multi-subtype FIV vaccines |
US6254572B1 (en) * | 1996-11-22 | 2001-07-03 | Liebel Flarsheim Company | Medical fluid injector having watchdog circuit |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021119459A3 (en) * | 2019-12-11 | 2021-10-07 | Illumina, Inc. | Immobilization in flow cells |
Also Published As
Publication number | Publication date |
---|---|
US20030180327A1 (en) | 2003-09-25 |
US6254872B1 (en) | 2001-07-03 |
US6544528B1 (en) | 2003-04-08 |
US7267824B2 (en) | 2007-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090263417A1 (en) | Multi-subtype FIV vaccines | |
US20080145381A1 (en) | Multi-subtype FIV vaccines | |
US20210386851A1 (en) | Materials and methods for detecting, preventing, and treating retroviral infection | |
CA2525641A1 (en) | Materials and methods for immunizing against fiv infection | |
YAMAMOTO | Patent 2230029 Summary | |
MXPA98001570A (en) | Feline immunodeficiency vaccines of subtipos multip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |